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                                                            ABSTRACT 
    Multivalency is an important phenomenon that guides numerous biological 
interactions. It has been utilized in design of therapeutics and drug candidates. Hence, 
this study attempts to develop analytical tools to study multivalent interactions and design 
multivalent ligands for drug delivery and therapeutic applications. 
    Atomic Force Microscopy (AFM) has been envisioned as a means of nanodiagnostics 
due to its single molecule sensitivity. However, the AFM based recognition imaging 
lacks a multiplex capacity to detect multiple analytes in a single test. Also there is no user 
friendly wet chemistry to functionalize AFM tips. Hence, an uncatalyzed Click 
Chemistry protocol was developed to functionalize AFM tips. For multiplexed 
recognition imaging, recognition heads based on a C3 symmetrical three arm linker with 
azide functionalities at its ends were synthesized and the chemistry to attach them to 
AFM tips was developed, and these recognition heads were used in detecting multiple 
proteins simultaneously using AFM. 
    A bis-Angiopeptide-2 conjugate with this three-arm linker was synthesized and this 
was conjugated with anti-West Nile virus antibody E16 site specifically to target 
advanced West Nile virus infection in the Central Nervous System. The bis-
Angiopeptide-2 conjugate of the antibody shows higher efficacy compared to a linear 
linker-Angiopeptide-2 conjugate of the antibody in in vitro studies and currently the 
efficacy of this antibody conjugate in studied in mice. Surface Plasmon Resonance 
imaging (SPRi) results indicate that the conjugation does not affect the antigen binding 
activity of the antibody very significantly. 
  
ii 
    A Y-shaped bisbiotin ligand was also prepared as a small sized antibody mimic. 
Compared to a monovalent biotin ligand, the y-Bisbiotin can cooperatively form a 
significantly more stable complex with streptavidin through intramolecular bivalent 
interactions, which were demonstrated by gel electrophoresis, SPR and AFM. Continuing 
on these lines, a four-arm linker was synthesized containing three single chain variable 
fragments (scFv) linked to the scaffold to form a tripod base, which would allow them to 
concomitantly interact with a trimeric Glycoprotein (GP) spike that has a “chalice” 
configuration. Meanwhile, a human IgG1 Fc is to be installed on the top of the 
tetrahedron, exerting effector functions of a monoclonal antibody. 
    
 
 
  
 
 
 
 
 
                                                     
                                                    
                                                      
 
  
iii 
                                                   ACKNOWLEDGMENTS 
    First and foremost I would like to express my deepest gratitude to my advisors Dr. 
Stuart Lindsay and Dr. Peiming Zhang for giving me the opportunity to work under their 
supervision. They have been outstanding mentors throughout the period of my graduate 
studies. Their expertise, understanding, generous guidance and support made it possible 
for me to work on research topics that were very interesting to me. I would also like to 
thank them for giving me the opportunity to work in synthetic chemistry as well as 
protein bioconjugation apart from using analytical tools like AFM and SPR. I am hopeful 
that the kind of expertise I have gained in this lab will help me further in my career. No 
words of gratitude is sufficient for Professor Ian Gould for his constant support from the 
very first day when I came here. I would also like to thank Dr. Nicholas Stephanopoulos 
for his helpful suggestions and supervision. 
    I would also like to extend my gratitude to Dr. Qiang Chen and Dr. Huafang Lai for 
collaborating with me on my projects.  I would also like to thank Dr. Subhadip Senapati 
for mentoring me and teaching me how to use the AFM. I am also extremely grateful to 
Ian Shoemaker for assistance with SPRi experiments. I would also like to thank Brian 
Cherry for teaching me how use the NMR and Natalya Zolotova for HRMS sample 
analysis. I would like to thank my coworkers Dr. Sudipta Biswas, Dr. Sovan Biswas, Dr. 
Suman Sen, Dr. Jong-one Im, Dr. Yanan Zhao, Dr. Pei Pang and Dr. Brian Ashcroft for 
their helpful suggestions. It was fun working with you guys. I would like to express my 
sincerest gratitude to Margaret Black and Mike Dodson for their constant support over 
the years. 
  
iv 
     I would like to thank my parents, my brother and my friends in USA and in India for 
their constant support and assistance. Last but not the least, I would like to thank my 
beautiful girlfriend, Sampa Maiti for everything. Your love and support has been the 
greatest inspiration. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   
 
 
  
v 
                                                    TABLE OF CONTENTS  
          Page 
 LIST OF TABLES....……………...……………………………………………………..viii  
 LIST OF FIGURES..…….....…………………………...…………………………………ix  
  LIST OF SCHEMES…………………………...………………………………………....xii 
 LIST OF ABBREVIATIONS….…….…......…………………...……....………………..xiv 
      CHAPTER 
1 INTRODUCTION............................................................................................................1  
    1.1  Multivalent Biomolecular Interactions…………………..…………………….......1 
    1.2  Synthetic Multivalent Biomolecules………………………………………….........3 
    1.3  Delivery of Therapeutics to the Central Nervous System………………………....8 
    1.4 Atomic Force Microscopy as a Tool to Study Biomolecular Interactions………...12                        
2 APPLICATION OF AFM TO STUDY MULTIVALENT INTERACTIONS…..……19 
    2.1 Introduction………………………………………………………………….….…19 
    2.2 Application of Catalyst-Free Click Reactions in Attaching Affinity Molecules….19 
          2.2.1 Introduction………………………………………………..……………...…19 
 
          2.2.2 Results and Discussion…………………………………..……………….…22 
 
          2.2.3 Experimental Details…………………………………………………...……30 
 
          2.2.4 Conclusion…………………………………………………………..…...….37 
 
    2.3 Interactions of a Dipeptide with Universal Reader ICA on a Gold Substrate…….38 
 
          2.3.1 Introduction………………………………………...………..………………38 
  
vi 
CHAPTER                                                                                                                    Page 
 
          2.3.2 Results and Discussion……………………………………………...…...….39 
 
          2.3.3 Experimental Details……………………………………………...………....41 
 
          2.3.4 Conclusion……………………………………………………...…………...43 
 
    2.4 A Three-Arm Scaffold Carrying Affinity Molecules for Multiplex Recognition  
 
          Imaging by Atomic Force Microscopy……………………………………...…….43 
 
          2.4.1 Introduction……………………………………………...…………..….…...43 
 
          2.4.2 Results and Discussion……………………………………...………...…….45 
 
          2.4.3 Experimental Details……………………………………………...…...…….59 
 
          2.4.4 Summary……………………………………….…………………………....68 
 
3 MOLECULAR TROJAN HORSE TO TARGET ADVANCED WEST NILE VIRUS     
INFECTION…………………………………………...………………………………...69 
    3.1 Introduction…………………………………………………...…………….……..69 
 
    3.2 Results and Discussion……………...…………………………………….………71 
 
    3.3 Experimental Details…………...…………………………………….……………84 
 
    3.4 Summary………………………………...…………...……………………………92 
 
4 SYNTHESIS OF MULTIVALENT CONSTRUCTS TO MIMIC ANTIBODIES…...93 
 
    4.1 Introduction…………………………………………………………………...…...93 
 
    4.2 Synthesis of a Y-shaped Scaffold for Building Small-Sized Antibody Mimics......91 
 
          4.2.1 Introduction……………………………………………………….........…....91 
 
          4.4.2 Results and Discussion……………………………...…………..…….....….94 
   
          4.2.3 Experimental Section……………………………………………………..…98 
  
vii 
CHAPTER                                                                                                                    Page 
 
          4.2.4 Conclusion……………………………………………………..….....…….108 
 
    4.3 Biochemical Construction of a Tripod Antibody to Target Ebola Virus……...…109 
 
          4.3.1 Introduction……………………………...……………...…..………..…….109 
 
          4.3.2 Results and Discussion………………………..…..……………………….112 
 
          4.3.3 Experimental Section…………………………………………..…..……....116 
 
          4.3.4 Summary…………………………………………………..…..……….......122 
REFERENCES....... …………………………………………………………..…..…....123 
APPENDIX 
   A COPYRIGHT PERMISSIONS……………………………………………...……..135 
  
            
        
 
 
 
 
 
 
 
 
 
 
                                                            
                                                      
  
viii 
                                                            LIST OF TABLES 
 
Table                                                                                                                               Page 
 
3.1   Kinetic Analysis of SPRi Data……………………………………………………83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ix 
                                                         LIST OF FIGURES 
Figure                                                                                                                             Page           
1.      Structural and Functional Valency……………………………….………………….1 
2.      Multivalency…………………………………………………………….…………..2 
3.      Intraspike Crosslinking in Di-Fabs……………………………………….…………..5 
4.      Bispecific CovX-Body………………………………………………………….…...6 
 
5.      TLR Triagonists……………………………………………………………………..6 
 
6.      Antibody-Recruiting Small Molecules……………………………………………...7 
 
7.      Synthetic Antibody Mimics Targeting Prostrate Cancer…………………………....7 
 
8.      Normal Capillary and Blood-Brain Barrier………………………………………....8 
 
9.      Potential Routes for Transport across BBB………………………………………....9 
 
10.    Molecular Trojan Horse……………………………………………………...….....11 
 
11.    Radiolabelled Enzyme-Trojan Horse Protein Conjugate………………………..…11 
 
12.    Basic AFM Principle…………………………………………………………….....12 
 
13.    Interactions during AFM Measurements……………………………………...…...13  
 
14.    Typical Force Distance Curve…………………………………………….……….15 
 
15.    Oscillation Amplitude of AFM Tip………………………………………………..16 
 
16.    Simultaneous Topography and Recognition Imaging…………………………...…17  
 
17.    Simultaneous Topography and Recognition Imaging………………………...……18 
 
18.    Copper Free Click Chemistry for Attaching Affinity Molecules to AFM Tips…...21  
 
19.    Functionalizing AFM Tips with Affinity Molecules………………………………26  
 
20.    Force-Distance Curves…………………………………………………………..…27 
  
x 
Figure                                                                                                                             Page           
21.    Force-Distance Histograms……………………………………………………..….28 
 
22.    Topographic and Recognition Images………………………………………...…...29 
 
23.    Force Spectroscopy of Glycine-ICA Interaction………………………………......40 
 
24.    AFM Tip Functionalized with Recognition Head…………………………………44 
 
25.    Chemical Structures of Recognition Heads……………………………………..…47 
 
26.    Synthesis of RH-1………………………………………………………………….48 
 
27.    Synthesis of RH-2……………………………………………………………....….50 
 
28.    Attaching Recognition Heads to AFM Tips………………………………….........51 
 
29.    Force-Distance Curves of RH-1 against VEGF………………………………........52 
 
30.    Topography and Recognition Image of VEGF and TNF-α Mixture…………........53 
 
31.    Superimposed Recognition Images…………………………….……………….….56 
 
32.    AFM Images with Different Tips and Substrates……………….………….......….57 
 
33.    Topography and Recognition Image of Thrombin and Integrin α5β1 Mixture........58 
 
34.    Structure of Molecular Trojan Horse…………………….…………………..…….70 
 
35.    Structure of Three Arm linker…….……………………………………..…………72 
 
36.    HPLC Chromatogram of Reaction between Ar3 and Angiopeptide-2….…………73 
 
37.    Fluorescence Spectroscopy of Lucifer Yellow Conjugates…………….………….74 
 
38.    Reaction of BCN Functionalized hE16 with Alexa Fluor Azide 3………….…......76 
 
39.    Reaction of BCN Functionalized hE16 with Alexa Fluor Azide 4……….…..…....77 
 
40.    Conjugation of BCN-E16 with CJ1…………………………….………………….78 
41.     Maldi-MS of E16 and E16-CJ1…………………………………………………...79 
  
xi 
Figure                                                                                                                             Page      
 
42.    Scheme of SPRi Apparatus……………………………………………………......81 
 
43.    Scheme of SPRi Experiment………………………………………………………82 
 
44.    Typical SPRi Curve for DIII Binding……………………………………...………82 
 
45.    Antigen Binding Activity and Cell Binding Activity of Conjugates…...………….84 
 
46.    Biotin-Streptavidin Complex…………………………………………...………….95 
 
47.    Tripod Antibody…………………………………………………...……………...112 
 
48.    Structure of 4-Arm Linker………………………………………………...……...113 
 
49.    Fluorescence Gel of Sortase A Mediated Ligation of c6D8 Protein…………......115 
 
50.    Time Course of Sortase A Mediated Ligation…………………………………....116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                               
 
 
 
                                                            
  
xii 
                                                        LIST OF SCHEMES 
 
Scheme                                                                                                                           Page 
 
2.2.1 Schematic Diagram of Chemical Synthesis……………………………………......23 
 
2.2.2 Tethering of Molecular Linkers to Affinity Molecules…………………………....25 
 
2.3.1 Attachment of Cys-Gly and Hexanethiol to Vinylsulfone Linker and ICA Reader to  
 
Gold Coated Mica Substrate…………………………………………………………..…39 
 
2.4.1 Synthesis of Three-Arm linker………………………………………………….….46 
 
2.4.2 Synthesis of Compound 2………………………………………………………….60 
 
2.4.3 ADIBO Functionalization of DNA Aptamers…………………………………......62 
 
3.1    Oxidation of hE16 with Sodium Periodate………………………………………...74 
 
3.2    Synthesis of Compound 2………………………………………………………….75 
 
3.3    BCN Modification of hE16………………………………………………………...75 
 
3.4    Synthesis of E16-CJ2………………………………………………………………80 
 
3.5    Syntheis of Compound 5…………………………………………………………...87 
 
3.6    Synthesis of Compound 4………………………………………………………….88 
 
4.2.1 Synthesis of y-Bisbiotin Ligands………………………………………………..…98 
 
4.2.2 Synthesis of 1-(tert-butoxycarbonylamino)-17-p-iodobenzyloxy-3n15
3- 
 
pentaoxaheptadecane…………………………………………………………………….99 
 
4.2.3 Synthesis of S4b…………………………………………………………………..101 
 
4.2.4 Synthesis of S7a and S7b…………………………………………………………102 
 
4.3.1 Synthesis of Compound 4………………………………………………………...114 
 
4.3.2 Synthesis of Compound 6………………………………………………………...114 
  
xiii 
Scheme                                                                                                                           Page 
 
4.3.3 Synthesis of Compound 2………………………………………………………...118 
 
                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
  
xiv 
                                                     LIST OF ABBREVIATIONS 
 
ADIBO            Aza-dibenzocycloctyne 
 
AFM                Atomic Force Microscopy 
 
ANGII             Angiopeptide-2 
 
APS                 1-(3-aminopropyl)silatrane 
 
APTES            (3-aminopropyl)triethoxysilane 
 
ARMs             Antibody –recruiting small molecules 
 
BBB                Blood-Brain Barrier 
 
BCN                (1R, 8S, 9R)-bicyclo6.1.0non-4-yn-9-ylmethanol 
 
br                     broad 
 
CNS                Central Nervous System 
 
                      Chemical shift (ppm) 
 
d                      doublet 
 
dd                    doublet of doublet 
 
DCM               Dichloromethane 
 
DFT                Density Functional Theory 
 
DMF               Dimethylformamide 
 
DMSO            Dimethyl sulfoxide 
 
DNA               Deoxyribonucleic Acid 
 
EBOV             Ebola Virus 
 
EDC                1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
 
ELISA             Enzyme-linked Immunosorbent Assay 
  
xv 
ELSD              Evaporative Light Scattering Detector 
 
Fab                  Fragment antigen-binding 
 
Fc                    Fragment crystallizable 
 
FTIR               Fourier transform Infrared spectroscopy 
 
GP                  Glycoprotein 
 
HIV                Human Immuno Deficiency Virus 
 
HPLC             High Performance Liquid Chromatography 
 
Hz                   Hertz 
 
ICA                 4(5)-(2-mercaptoethyl)-H-imidazole-2-carboxamide 
 
IgG                  Immunoglobin G 
 
kD                   kilodaltons 
 
LOD                Limit of detection 
 
LRP                 Lipoprotein receptor-related protein 
 
m                     multiplet 
 
Mab                 Monoclonal antibody 
 
MALDI-MS    Matrix Assisted Laser Desorption/Ionization Mass Spectrometry 
 
MALDI-TOF  Matrix Assisted Laser Desorption/Ionization-Time of Flight 
 
mg                   milligram 
 
mL                   milliliters 
 
mM                  millimolar 
 
mmol               millimoles 
 
mRI                 Multiplex Recognition Imaging 
  
xvi 
mV                  millivolts 
 
m/z                  mass to charge ratio 
 
NF               Nuclear factor Kappa-light-chain-enhancer of activated B cells 
 
ng                    nanograms 
 
NHS                N-hydroxysuccinimide 
 
nm                   nanometer 
 
nM                   nanomlar 
 
nN                   nanonewton 
 
N/m                 Newtons per meter 
 
NMR               Nuclear Magnetic Resonance 
 
OEG                Oligo(ethyleneglycol) 
 
PBS                 Phosphate buffered saline 
 
PDB                Protein Data Bank 
 
PEG                Polyethylene glycol 
 
pI                     Isoelectric point 
 
pN                   piconewton 
 
RI                    Recognition Imaging 
 
RNA                Ribonucleic Acid 
 
ROI                  region of interest 
 
RP-HPLC        Reverse phase-High performance liquid chromatography 
 
RT                    Recognition Tunneling 
 
RU                   Response unit 
  
xvii 
s                       singlet 
 
ScFv                Single chain variable fragment 
 
SEC                 Size Exclusion Chromatography 
 
SPRi                Surface Plasmon Resonance Imaging 
 
STM                Scanning Tunneling Microscope 
 
SyAm-Ps         Synthetic antibody mimics targeting prostrate cancer 
 
t                       triplet 
 
TBA                Thombin binding aptamer 
 
TCEP              Tris(2-carboxyethyl)phosphine 
 
TCO                (E)-cyclooct-4-enol 
 
TEAA             Triethylamino acetate 
 
TFA                Trifluoroacetic acid 
 
THF                Tetrahydrofuran 
 
THPTA            tris(3-hydroxypropyltriazolylmethyl)amine 
 
TLC                 Thin layer chromatography 
 
TLR                 Toll-like receptor 
 
TNF                 Tumor Necrosis Factor 
 
TREC               Simultaneous Topography and Recognition Imaging 
 
g                     micrograms 
 
L                    microliters 
 
M                   micromole 
UV                   Ultra-violet 
 
  
xviii 
VEGF              Vascular endothelial growth factor 
 
WLC                Worm Like Chain 
 
WNV                West Nile Virus
  
1 
                                                           CHAPTER 1 
                                                        INTRODUCTION 
 
1.1 Multivalent Biomolecular Interactions 
Valency of a biological entity is defined as the number of structural units of the same or 
similar type that are connected to the entity.1 The maximum valency of the biological 
entity that is threotically possible based on the number of ligands attached to the 
multivalent construct is known as structural valency while the valency employed during 
multivalent association is known as functional valency. 
 
 
Figure 1. Structural and Functional valency. Adapted from reference (1) copyright 2000 
John Wiley & Sons 
n
nn
monovalent ligand monovalent receptor monovalent association
multivalent ligand multivalent receptor multivalent association
   trivalent ligand
(structural valency)
   trivalent receptor    trivalent ligand
(structural valency)
divalent association
(functional valency)
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Various biological ligands are known to display polyvalency as the unique collective 
property due to multiple simultaneous interactions is different from properties displayed 
by individual constituents.2 There are various modes of multivalent binding such as 
statistical rebinding, chelation, clustering or subsite binding.3 
 
  
3 
Figure 2. A. Statistical rebinding B. Chelation C. Clustering D. Subsite binding. 
Reproduced with permission from reference (3) copyright 2013 Royal Society of 
Chemistry  
     Multisite binding prevents dissociation due to transient unbinding events and hence 
serves to increase affinity.3 There are various examples of application of multivalent 
interactions in natural biological ligands.  
   The influenza virus hemagglutinin binds trivalently to sialic acid on cell surfaces. The 
multivalent interaction involves tight binding while the monovalent interaction in 
weak.1,2 This has been employed in designing multivalent sialic acid inhibitors to target 
influenza viruses.4,5,6 Polymeric Vancomycin  have been found to interact with multiple 
copies of D-Ala-D-Ala, a cell wall precursor present in the gram-positive bacteria more 
strongly compared to the monovalent ligand are known to exhibit more potent anti-
bacterial properties.7 Mannose binding plant lectins like Concanavalin A are known to 
assemble into higher order aggregates depending on the pH.8, 9 A drug molecule has 
higher affinity and residence time to its target due to multivalent interaction.10  
   Hence, multivalency is an important phenomenon that guides most biological 
interactions. 
1.2 Synthetic Multivalent Bio-molecules 
 
    Multivalency has been utilized in design of therapeutics and drug candidates. For 
instance, thermodynamically, if two ligands of a bivalent molecule are unstrained and 
independent, the change of enthalpy in the bivalent association (Hbi) is two times as 
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much as that in the monovalent binding (Hmono).11 On the other hand, the structure 
should also have a minimal entropy loss when it binds to achieve the best outcome. In 
general, the entropy can be expressed as below:12 
 
where  takes into account all unfavorable entropic terms as a result of rotatable 
bonds becoming frozen when the bivalent ligand binds to its receptor. To achieve a 
highly positive cooperativity, the absolute value of should remain as small as 
possible. Also, it should be noted that a small difference in entropy results in a large 
change in the entropic term S, creating significant impact on the binding energy; 
however, some of the entropy cost can be paid in advance by preorganization.13 
Hence, study of multivalent interactions and design of multivalent scaffolds and linkers is 
of utmost importance. 
   High affinity (avidity) in antibodies arise due to bivalent crosslinking by the two Fabs. 
Most anti-HIV-1 antibodies are known to bind monovalently due to low density of 
glycoprotein spikes present in the virus and hence have low potency.14 However, two 
hetero Fabs connected together by a DNA linker can bind by intraspike cross-linking and 
are shown to have 2.5 fold increase in potency compared to its monovalently bound 
counterpart.14  
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Figure 3. Intraspike cross-linking in di-Fabs. Reproduced with permission from reference 
(11) copyright 2015 Elsevier. 
 
   Bispecific CovX-Bodies generated by site-specifically attaching pharmacophore 
peptide heterodimers to a scaffold antibody shows high efficacy and is known to have 
long half-life.15 
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Figure 4. Bispecific CovX-body. Reproduced with permission from reference (12) 
copyright 2010 National Academy of Sciences, USA. 
    Esser-Kahn and coworkers designed combinations of di and tri-agonists of Toll-like 
receptors (TLR) and the linked agonists showed increased activation of transcription 
factor NFκβ and enhanced and directed immune related cytokine production and gene 
expression beyond cells treated with an unconjugated mixture of agonists.16 
 
Figure 5. TLR Triagonist. Adapted from reference (13) 
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    Antibody-recruiting small molecules (ARMs) containing Target-binding terminus and 
Antibody-binding terminus have been shown to enhance binding between antibodies and 
disease-related pathogens thus facilitating immune-mediated clearance.17 
 
Figure 6. Antibody-recruiting small molecules (ARMs). Reproduced with permission 
from reference (14) copyright 2012 American Chemical Society. 
    Synthetic antibody molecules of intermediate size have been shown to simultaneously 
bind to target specific prostrate antigen and Fc gamma receptor I thus eliciting highly 
selective cancer cell phagocytosis.18 
 
Figure 7. Synthetic antibody mimics targeting prostrate cancer (SyAM-Ps). Adapted 
from reference (15) 
   Thus synthetic multivalent biomolecules has been employed with increased efficacy for 
targeted delivery. The design of multivalent synthetic reagents that can illicit enhanced 
immune response or can deliver biologics site-specifically is emerging as an important 
field of study. 
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1.3 Delivery of Therapeutics to the Central Nervous System 
All animals with a complex nervous system require a Blood-Brain Barrier (BBB). 19 
Structurally the BBB is formed by endothelial cells having tight junctions known as Zona 
Occludens. They form the capillary of the brain and spinal cord. Because the main role of 
the BBB is to protect neurons from circulations cytotoxic agents, the endothelial cells 
along with specialized brain cells such as Astrocytes and Pericytes practically restrict any 
free diffusion of solutes across the BBB.19, 20 
 
        Capillary (in General)                                            Blood-Brain Barrier (BBB) 
Figure 8. A normal capillary and the Blood-Brain Barrier. Reproduced with permission 
from reference (16) copyright 2004 Elsevier. Adapted from reference (17) 
    In absence of free diffusion there are a few potential routes for transport of solutes 
across the BBB. 
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Figure 9. Potential routes for transport across the BBB. Reproduced with permission 
from reference (16) copyright 2004 Elsevier. 
    Leucocytes may cross the BBB by modifying tight junctions. While solutes may 
passively diffuse based on their lipid solubility, there are some active efflux carriers that 
intercept some of these passively penetrating solutes and transport them out of the 
endothelial cell. Polar substrates like glucose, amino acids and nucleosides may get 
transported by carrier-mediated influx. Most macromolecules are transported through 
receptor mediated transcytosis while negatively charged macromolecules may also be 
transported by Absorptive-Mediated Transcytosis. Some polar solutes may get 
transported by Tight junction modulation resulting in relaxation of the junctions. 19 
    To transport therapeutics to the brain different strategies are employed: 21 
(i)  Invasive or transcranial delivery, 
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(ii) Increasing Lipid solubility of the drug, 
(iii) Reformulation of the drug to access endogenous BBB transporters.  
     While carrier mediated transporters have been successfully utilized to transport small 
molecule drugs conjugated with various essential analytes like glucose, amino acids, 
hexoses and vitamins that have carrier mediated transport systems embedded within the 
BBB, the most popular way to transport macromolecular drugs to the brain is by receptor 
mediated transcytosis by taking advantage of peptide specific receptor transporters 
located on the capillary endothelium.21, 22 This has given rise to the Molecular Trojan 
Horse technology for delivery of therapeutics. A macromolecular drug or a non-viral 
plasmid DNA or a monoclonal antibody is attached to a vector that can access a specific 
catalyzed transport machinery leading to the transport of the drug across the BBB.21-24 A 
radio-labelled recombinant lysosomal enzyme iduronate-2-sulfatase fused with a 
radiolabeled monoclonal antibody against human insulin receptor shows the penetration 
of the conjugate to all parts of the brain whereas iduronate-2-sulfatase does not cross the 
BBB. 25 
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Figure 10. Molecular Trojan Horse technology. Reproduced with permission from 
reference (18) copyright 2006 Elsevier. 
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Figure 11.  Radiolabeled enzyme-Trojan horse protein conjugate shows distribution to all 
parts of brain. Reproduced with permission from reference (22) copyright 2012 American 
Chemical Society. 
1.4 Application of Atomic Force Microscopy as a Tool to Study Biomolecular 
Interactions 
     Understanding single molecular interactions forces is a challenging task in molecular 
and structural biology.26 The advent of probe microscopes particularly the atomic force 
microscope (AFM) has revolutionized this field.26-28 The AFM consists of a sharp tip 
mounted on top of a cantilever. The tip can scan over a surface in x-y direction to give 
rise to a topographic image of the sample and it can also be moved in the z direction, first 
downwards until it contacts the surface and then upwards till no interactions between the 
probe and the substrate are felt giving rise to a resulting plot (force curve) of the 
cantilever deflection versus the separation of the probe and the substrate.26 
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Figure 12. Basic AFM Principle. Adapted from Agilent 5500 manual. 
     There are two modes of AFM, the contact (static) mode in which the tip approaches 
the substrate and is the pushed into the substrate and finally retracted back and the 
dynamic mode in which the cantilever oscillates with a certain frequency. The dynamic 
mode can be operated in the acoustic mode in which the cantilever is oscillated above the 
surface near its resonance frequency and the magnetic mode in which a magnetically 
coated cantilever is oscillated using a magnetic ac field. Figure 12 shows the interactions 
between the scanning tip and the sample during different modes of AFM measurements.29  
 
Figure 13. Interactions during AFM measurements. Adapted from reference (26). 
  
14 
    In a further modification of the AFM, Lieber and coworkers developed the chemical 
force microscopy by which the probe tips can be molecularly functionalized to measure 
forces of interaction with organic monolayer functionalized surface.30 This method has 
been employed in studying interactions between biomolecules and revolutionized our 
way understanding single molecule biomolecular interactions.31 Some examples of 
biomolecular interactions studied using AFM include integrin binding to fibrinogen,32-34 
lectin binding to carbohydrates35,36 aptamer-protein interaction37,38 antigen-antibody 
interactions39-41 etc. Generally a flexible linker such as polyethylene glycol is attached to 
the tip to tether ligands during imaging and force measurements. The linker serves as a 
spacer between the tip and the ligand and prevents non-specific interactions between the 
tip and the substrate. 
     Thus, the AFM is a powerful tool not only for its ability to image samples with 
nanometer resolution, but also to measure single molecule interaction forces in the order 
of piconewtons. The force spectroscopy is performed in contact mode. A typical force-
distance curve is shown in Figure 14.42 During force spectroscopy a tip functionalized 
with a recognition molecule (such as aptamer, antibody etc.) is brought in contact with 
the surface coated with a monolayer of the corresponding cognate protein or biomolecule 
that can bind with the recognition moiety attached to the tip, following which the tip is 
retracted to its original position. During retraction the linker gets stretched due to 
interaction between the recognition moiety and the surface protein following which the 
cantilever bends and finally unbinding occurs and the retraction curve comes back to zero 
force. The unbinding force between the recognition moiety and the protein on the surface 
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can be measured from the resulting force curve by employing the Hooke’s law: F = - kcd, 
where F is the force acting on the cantilever, kc is the spring constant of the cantilever, 
and d is its deflection. During force spectroscopy experiment the approach and retraction 
of the tip is performed a number of times to generate force curves following which a 
histogram is plotted with the unbinding force data obtained from the force curves. The 
mean unbinding force can then be calculated by fitting the histogram. 
 
Figure 14. Typical force distance curve. Reproduced with permission from reference 
(39) copyright 2011 Nature Publishing Group. 
    The AFM is popularly known for imaging samples with nanometer resolution. During 
AFM imaging a harmonically oscillating tip is scanned over the surface in X-Y direction. 
During to interactions of the molecules on the surface the minima of the oscillations 
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changes giving rise to a corresponding topography image. However if a cantilever 
containing a tip functionalized with a recognition molecule is scanned over the surface, 
due to changes in the topography the minima of the oscillations changes while the 
maxima changes if there is an interaction between the functionalized tip and the 
substrate.43,44 
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Figure 15. Oscillation amplitude with (A) Bare tip (B) Functionalized tip. Reproduced 
with permission from reference (40) and (41) copyright 2016 American Chemical Society 
and 2004 Biophysical Society. 
The changes in the minima of the amplitude of oscillation amplitude gives rise to a 
topographic image which appears as white spots while changes in maxima of the 
amplitude gives rise to a recognition image which appears as black spots. During 
imaging, the TREC box separates the maxima and the minima of the oscillation 
amplitude and the topography and recognition image gets generated simultaneously.45 
The recognition imaging has an advantage that it does not require any tags or labels like 
most other techniques and has resolution in the range of about 20 nm. The specificity of 
the recognition experiment is checked by passing a blocking solution to block the ligand 
on the tip. Once this ligand gets blocked, the tip generates no more recognition. 
 
 
Figure 16. Simultaneous Topography and Recognition (TREC) Imaging. Reproduced 
with permission from reference (40), (41) and (42) copyright 2016 American Chemical 
Society and 2004 Biophysical Society and 2005 John Wiley & Sons, Inc. 
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Figure 17. Simultaneous Topography and Recognition (TREC) Imaging. A. Topography 
B. Recognition. Reproduced with permission from reference (40) copyright 2016 
American Chemical Society. 
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                                                            CHAPTER 2 
       APPLICATION OF AFM TO STUDY MULTIVALENT INTERACTIONS 
2.1. Introduction 
    The human proteome consists of millions of proteins, many of which occur in minute 
concentrations below limits of detection (LOD) of current technologies such as ELISA, 
mass spectrometry, and protein microarrays. Therefore, there is a long felt need of a 
molecular tool capable of directly detecting those disease relevant protein biomarkers 
present in low abundance without any additional manipulation such as post assay signal 
amplification. 
    AFM has developed into a surface imaging tool with nanometer spatial resolution and 
an important nanobiotechnique. A ligand attached to an AFM tip with a flexible 
polyethylene glycol linker can be used to scan over a surface to measure the forces of 
interactions (force spectroscopy) or to generate a map of these interactions (recognition 
imaging). Thus AFM has been envisioned as a means of nanodiagnostics due to its single 
molecule sensitivity. However, compared to fluorescence microscopy, the AFM based 
recognition imaging lacks a multiplex capacity to detect multiple analytes in a single test. 
Hence, our idea was to synthesize recognition heads, develop a chemistry to attach them 
to AFM tips, and further implementation in detecting multiple proteins simultaneously. 
2.2. Application of Catalyst-Free Click Reactions in Attaching Affinity Molecules to 
Tips of Atomic Force Microscopy for Detection of Protein Biomarkers 
2.2.1. Introduction 
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    During AFM imaging and force spectroscopy a molecular linker is often employed to 
attach affinity molecules to AFM tips, which provides an advantage in distinguishing 
between specific and nonspecific interactions.46 The heterobifunctional poly[ethylene 
glycol] (PEG) has become a commonly used linker for this purpose. 47,48 The popular 
attachment is a three-step process that includes functionalizing an AFM tip with a 
chemically reactive group, tethering the PEG linker to the AFM tip, and reacting with an 
affinity reagent. (3-Aminopropyl)triethoxysilane (APTES) is a choice reagent for 
amination of silicon tips49,50, but it is notoriously problematic for forming uniform 
monolayers, especially when the reaction is carried out in a liquid phase. 51,52 APTES 
should be freshly redistilled before use in order to achieve reproducible results. Chemical 
vapor deposition of APTES has been developed to improve the outcome,50 but the 
process is tedious, requiring a thorough purge of the deposition chamber with argon to 
remove trace of moisture. Without developing an automated apparatus, it is difficult to be 
scaled up. The reaction of amine with N-hydroxysuccinimide (NHS) ester has been one 
of the most commonly used methods for tethering carboxylated PEG linkers to AFM 
tips.53-57 The NHS ester is sensitive to moisture and is prone to rapid hydrolysis with 
increasing in pH (a half-life time of 4−5 h at pH 7 and 1 h at pH 8).58,59 On the other 
hand, the amine exists in an ammonium form at the neutral pH, requiring basic conditions 
to be deprotonated for its nucleophilic activity. These caveats make it difficult to handle 
the NHS ester reaction in aqueous solutions, and one has to fine-tune pH and reaction 
time in order to achieve optimal outcomes. 
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    Hence, we have developed a new scheme for attachment of affinity molecules to AFM 
tips based on Click Chemistry.60 
 
Figure 18. Copper-free Click Chemistry approach for attachment of affinity molecules to 
AFM tips. Adapted from reference (57). 
Chen et al. have employed a copper-catalyzed alkyne−azide reaction to attach antibodies 
to a gold coated AFM tip through an azido-PEG-thiol linker.61 To take it further, we 
implement two orthogonal catalyst-free click reactions for the attachment of affinity 
molecules to silicon tips. First, we have synthesized a molecular anchor composed of 
cyclooctyne and silatrane for the introduction of an alkyne function to the silicon tip. In 
aqueous solution, the silatrane moiety reacts with silanols on silicon surfaces to form a 
monolayer. It has been known that silatrane is less reactive than alkoxysilanes and 
extremely resistant to polymerization at a neutral pH.62 Lyubchenko and co-workers have 
employed 1-(3-aminopropyl)silatrane (APS) as a substitute of APTES in 
functionalization of AFM tips and mica surfaces. 63-66 Thus, we expected that the new 
anchoring molecule would form a uniform cyclooctyne monolayer on the silicon tips. 
The ring strained cyclooctyne promotes the alkyne−azide reaction without the copper 
catalyst.67 In addition, we have synthesized a new class of molecular linkers, azido-PEG-
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vinyl sulfone with defined lengths, for connection of affinity molecules to AFM tips. In 
the present study, we have focused on attaching thiolated oligonucleotide aptamers and 
affinity peptides to AFM tips because they are rapidly growing areas in molecular 
diagnostics.68 The reaction of vinyl sulfone with thiol in aqueous solution comprises 
another category of click chemistry in bioconjugation,69 being used for the labeling 
of proteins70 and proteomes.71 We adapt it as a first click reaction to connect thiolated 
affinity molecules to the PEG linker as illustrated in Figure 17. The second click (azide to 
alkyne) finishes the process of the attachment. These two click reactions are orthogonal 
so that there is no cross talk between each other. 
2.2.2. Results and Discussion 
    Synthesis. The molecular anchor (3) was synthesized simply by reacting APS (1)66 
with 2-(cyclooct-2-yn-1-yloxy)-acetic acid (2)72 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, Scheme 2.2.1a). The desired product was 
separated as a white solid by silica gel chromatography with a yield of 60%. The 
molecular linker for Recognition Imaging (RI) (6a,Scheme 2.2.1b) was synthesized 
starting from hexaethylene glycol. First, azido-(CH2CH2O)6-Ts (4, Ts = Tosyl) was 
synthesized in a multigram scale following a method reported in literature.73,74 Azido-
(CH2CH2O)12-H (5) was prepared in a 71% yield by reacting 4 with sodium 
hexaethylene glycoxide (3 times excess) that was generated in situ by treating 
hexaethylene glycol with sodium hydride. In presence of potassium t-butoxide, 5 reacted 
with divinyl sulfone to furnish the desired product 6a in a fairly good yield (64%). In the 
same manner, the linker azido-(CH2CH2O)36-vinyl sulfone (6b) was synthesized by 
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reacting azido-dPEG36-alcohol with divinyl sulfone in a yield close to that of 6a (Scheme 
2.2.1c). These two products were characterized with FTIR, NMR, and mass 
spectroscopy.  
Although it has been reported that vinyl sulfones react with azides in presence of CuSO4 
and sodium ascorbate,75 we found by NMR monitoring that 6a and 6b were stable both in 
its pure form and in chloroform at room temperature at least for two days. Maleimide is 
another widely used reactive group that functions similarly to vinyl sulfone in 
bioconjugation,76 but it may not be amenable to coexisting with azide because a [3 + 2] 
cycloaddition could spontaneously take place between these two functions in some 
circumstances.77 In addition, maleimide can undergo the thiol exchanges and ring 
hydrolysis (above pH 8),78,79 which would complicate outcomes of the conjugating 
reaction. It is also a reason why we chose vinyl sulfone as a Michael addition receptor of 
thiols in our attachment chemistry. 
 
  
24 
Scheme2.2.1. Schematic diagram of chemical synthesis. 
Click 1: Tethering Molecular Linkers to Affinity Molecules.  
Two affinity molecules, thrombin-binding DNA aptamer (TBA)80 and cyclic RGDfC 
peptide containing a RGD motif that binds to integrin receptors such as α5β1,81 were 
chosen to study the attachment chemistry. First, the disulfide at the 3′-end of the DNA 
aptamer from custom synthesis was reduced to thiol using tris(2-carboxyethyl)phosphine 
(TCEP), which then reacted with linker 6a and 6b at pH 8.0 in phosphate buffered 
aqueous solutions, respectively. Through the Michael addition of thiol to vinyl sulfone 
(Scheme 2.2.2a), the DNA aptamer was converted to azido-PEGylated products D-1a 
with a 95% yield and D-1b with a 89% yield, based on HPLC analysis. The disulfide 
DNA was used as a negative control, and it did not react with 6a and 6b, implying that 
the vinyl sulfone is specific to thiol under the current conditions. Also, we observed that 
the reaction between the vinyl sulfone and the thiolated DNA at pH 7−7.5 was very slow 
and did not complete even after 1 day. The thiol reaction is driven by the thiolate that is a 
much stronger nucleophile than its conjugate acid thiol. Since the alkylthiol is fairly 
acidic with pKa of about 10−11, the increase of pH surely increases existence of the 
thiolate anion, resulting in an increased reaction rate. This is consistent with what has 
been reported in literature.82 Under similar conditions, the thiolated RGDfC was 
converted to products P-1a and P-1b quantitatively (Scheme 2.2.2b). We did not observe 
any side products by MALDI mass spectrometry and reverse phase HPLC analysis. In 
addition, no apparent time differences between reacting with 6a and 6b were observed. In 
sum, all these reactions were completed within 3 h when starting with DNA or peptides 
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in a range of millimolar concentrations. It should be noted that the vinyl sulfone also 
reacts with alkyl amines under basic conditions.83 In our case, the amine functionalized 
aptamer and the cyclic RGDfK reacted with both 6a and 6b in phosphate buffered 
solutions at pH 8.8, but the reactions were very slow and not completed even after 10 h. 
This shows that the vinyl sulfone can specifically react with thiol in the presence of 
amino function with well-tuned pH. 
 
 
Scheme 2.2.2. Schematic Description of Tethering the Molecular Linkers to Affinity 
Molecules through the Michael Addition of Thiol to Vinyl Sulfone 
Click 2: Attaching Affinity Molecules to AFM tips. 
 We have developed a two-step protocol for the attachment. As illustrated in Figure 18, 
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a bare AFM tip is first functionalized with the molecular anchor 3 in aqueous solution, 
followed by reacting with the azide functionalized affinity molecules under physiological 
conditions. It is worth noting that all the reactions were carried out in aqueous solutions 
without using any organic solvents. The attachment chemistry has worked well on two 
different AFM tip materials: SiN tipped probes (from Olympus and Bruker) and silicon 
probes (from NanoWorld). Before the chemical functionalization, these tips were cleaned 
sequentially with UV-ozone and oxygen plasma to increase the silanol density on the 
silicon surface for the silanization reaction. 
 
Figure 19. Process of functionalizing AFM tips with affinity molecules: (a) coupling 
cyclooctyne to an AFM tip through silanization; (b) attaching affinity molecules to an 
AFM tip through alkyne−azide click reaction. 
Force Measurement. The attachment chemistry was validated by measuring forces of 
affinity molecules tethered to SiN tips unbinding from their protein cognates. The protein 
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samples were immobilized on APS-modified mica substrates using glutaraldehyde as a 
cross-linker according to a procedure reported in literature.84 Initially, we collected about 
1000 force−distance curves from each of measurement experiments with either D-1b 
against thrombin or P-1b against integrin α5β1. The blue solid lines in panels A and C of 
Figure 19 show typical retracting force−distance curves we used for data analysis, which 
accounts for more than one fourth of the collections. The selection was based on an 
assumption that a rupture directly related to unbinding of an affinity molecule from its 
protein cognate is likely to take place around the distance corresponding to the stretched 
length of a PEG linker (∼13.5 nm in our case). 
 
Figure 20. A. Force-distance curve for TBA-Thrombin unbinding, B. Distance histogram 
for TBA-Thrombin unbinding, C. Force-distance curve for RGD-Integrin unbinding, D. 
Distance histogram for RGD-Integrin unbinding. 
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Figure 21. A. Force histogram of TBA-Thrombin unbinding, B. Force histogram of 
RGD-Integrin unbinding. 
Recognition Imaging (RI). We did recognition imaging to confirm that our chemistry 
works with the RI technique. Unexpectedly, the recognition imaging of clinically relevant 
proteins thrombin and integrin has not been reported. It has been demonstrated that a 
PEG linker with 12 ethyleneoxy (CH2CH2O) units can effectively produce quality 
recognition images.85 Linker 6a was tailored for RI. Its conjugate D-1a or P-1a was 
attached to Ni-coated MacMode tips (from Nanoworld) following the same protocol as 
mentioned above. The protein samples (thrombin or α5β1integrin) were deposited on 
mica using the same glutaraldehyde chemistry. However, the optimal protein 
concentration (50 pg/μL in 1× PBS buffer, pH 7.4) for the RI was 20 times lower than 
that for the force measurements, which was predetermined by imaging the surface with 
bare AFM tips in the air mode, ensuring that the protein molecules were well distributed 
in a predefined area. For one measurement, only 2−3 μL of protein sample is needed in 
the current setup. Thus, a few femtomoles of proteins can readily be detected by the AFM 
based recognition imaging. Figure 21 shows the images obtained from our RI 
experiments. In general, RI simultaneously produces both topographic and recognition 
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images. Each bright round spot in the topographic image presumably represents a protein 
molecule (thrombin in panel A and integrin in panel D of Figure 21). This can be verified 
by examining the recognition images (panels B and E of Figure 21) where the dark spots 
represent recognition of those bright ones within the corresponding locations in the 
topographic image as expected protein molecules. We obtained about 77% recognition of 
thrombin and 84% recognition of integrin by comparison between their topography and 
recognition images. The recognition was further confirmed by the same blocking 
experiments as in the force measurements. After injecting a protein (thrombin or integrin) 
solution to the flow cell, most of the dark spots disappeared from the recognition images 
(panels C and F of Figure 22). These experiments demonstrate that our attachment 
chemistry works effectively for RI as well. 
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Figure 22. (A) Topographic image of thrombin proteins on mica. (B) Corresponding 
recognition image of (A). (C) Recognition image from using a thrombin solution to block 
the TBA tip. (D) Topographic of integrin proteins on mica. (E) Corresponding 
recognition imaging of (D). (F) Recognition image from using an integrin solution to 
block the RGD tip (the circles in the images indicate those protein molecules that were 
recognized, whereas the square indicates the protein that was not recognized). 
2.2.3. Experimental details. 
General information 
All chemicals were purchased from commercial suppliers (Sigma-Aldrich, Fluka, Santa 
Cruz Biotechnology, Alfa Aesar). Anhydrous organic solvents were Sure/SealTM from 
Aldrich. Thrombin aptamers were custom synthesized by IDT (Integrated DNA 
Technologies) and human α thrombin was purchased from Abcam, Azido-dPEG® 
36-alcohol was purchased from Quanta Biodesign, human α5β1 integrin from YO 
Proteins AB (Sweden), cylco(RGDfK) and cyclo(RGDfC) from Peptides international. 
All the synthetic reactions were carried out under nitrogen atmosphere. Thin layer 
chromatography (TLC) was used to monitor progress of organic reactions. An automated 
flash chromatography system (CombiFlash Rf, Teledyne Isco, Inc.) was used to separate 
the organic compounds with silica gel columns. FTIR data were collected using Thermo 
Scientific Nicolet™ 6700 FT-IR spectrometer. The HPLC purification was carried out in 
Agilent 1100 series equipped with a UV detector and a fraction collector. All the proton 
NMR (1H) spectra were recorded on a Varian 400 MHz instrument. 1H chemical shifts 
were referenced relative to the residual solvent peak (such as CDCl3: δH = 7.24 ppm). 
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MALDI-TOF analysis was performed on Voyager-DE STR instrument. Water was from 
Millipore’s Milli-Q water purification system with a real time monitor of total of carbon 
(TOC) connected to a BioPak Polisher to remove biological contaminates. TOC level is 
strictly maintained below 5 ppb and resistivity at 18.2 MG x cm. 
N-(3-(silatranyl)propyl)-2-(cyclooct-2-yn-1-yloxy)acetamide (3): 
EDC (115 mg, 0.6 mmol) was added to a solution of 2-(cyclooct-2-yn-1-yloxy)acetic acid 
(100 mg, 0.5 mmol) in anhydrous dichloromethane (2 mL). The solution was stirred for 
30 minutes, followed by the addition of APS (140 mg, 0.6 mmol). After 3 hours, the 
reaction was stopped by rotary evaporation to remove the solvent. The crude product was 
purified by flash chromatography in a silica gel column using a gradient of methanol (0-
5% over 3 h) in dichloromethane to give a white solid (130 mg, 60%). 1H NMR (400 
MHz, CDCl3): δ = 0.4 -0.44 (m, 2 H), 1.15 - 2.25 (m, 10 H), 1.58 - 1.64 (m, 2 H), 2.79 (t, 
6 H, J= 6 Hz), 3.24 (m, 2 H), 3.74 (t, 6 H, J = 6 Hz), 3.81 (d, 1 H, J = 15.2 Hz), 4.0 (d, 1 
H, J = 15.2 Hz), 4.2 (t, 1 H), 6.65 (s, 1H, broad); 13C NMR (50 MHz, CDCl3): δ = 13.2, 
20.6, 24.9, 26.2, 29.6, 34.2, 41.8, 42.1, 51.1, 57.7, 68.5, 73.0, 91.5, 101.3, 169.1. HRMS 
(FAB): m/z (M+H) calculated for C19H32+1N2O0Si: 397.2158; found: 397.2159.3 
Special note on nomenclature: To avoid excessive use of a long series of numbers, the 
mathematical shorthand for expressing arithmetic progressions is used to denote the 
positions of oxygen atoms in the elongated PEG chains, as proposed by Hii and 
coworkers.73 
35-azido-3n333-undecaoxapentatriacontan-1-ol (5): 
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Sodium hydride (0.71g, 29.5mmol) was added to a solution of hexaethylene glycol 
(6.42g, 22.7 mmol) in anhydrous tetrahydrofuran (THF) (40 mL) with stirring at 0 °C. 
After 1 hour, to the mixture a solution of compound 4 (3.5g, 7.5mmol) in anhydrous THF 
(20 mL) was added. The mixture was allowed to warm to room temperature, stirred for 
another 15 hours, to which methanol (5 mL) was added dropwise to stop the reaction. 
After removing the solvent, the crude product was purified in a silica gel column by flash 
chromatography using a gradient of methanol (0-5% over 4 h) in dichloromethane. 
Compound 5 was obtained as a colorless liquid (3.1g, 71%). 1H NMR (400 MHz, 
CDCl3): δ = 2.7 (s, 1 H, broad), 3.34 (t, 2 H, J = 4.8 Hz), 3.55-3.69 (m, 46 H); HRMS 
(APCI): m/z (M+H) calculated for C24H49+1N3O12: 572.3395; found: 572.3391. 
1-Azido-35-(2-(vinylsulfonyl)ethoxy)-3n333-undecaoxapentatriacontane (6a): 
To a solution of 5 (100 mg, 0.18 mmol) in anhydrous THF (2 mL), divinyl sulfone (180 
μL, 1.8 mmol) was added with stirring, followed by the addition of potassium t-butoxide 
(23 mg, 0.2 mmol). The reaction was monitored by thin layer chromatography (TLC). 
Within one hour, the starting material 5 was consumed and a less polar spot observed on 
the TLC plate. The reaction mixture was filtered, concentrated, and purified in a silica gel 
column by flash chromatography using 0-4% gradient (over 4 hours) of methanol in 
dichloromethane to furnish compound 6a as a colorless liquid (77 mg, 64%). FTIR (cm-
1): 1102 (S=O symmetric stretch), 1313 (S=O asymmetric stretch), 1605 (C=C stretch), 
2101 (N=N=N stretch), 3056 and 3097 (sp2 C-H stretch); 1H NMR (400 MHz, CDCl3): δ 
= 3.24 (t, 2 H, J = 5.2 Hz), 3.36 (t, 2 H, J = 5.2 Hz), 3.6-3.87 (m, 46 H), 3.88 (t, 2 H, J = 
5.2 Hz), 6.06 (d, 1 H, J = 9.6 Hz), 6.37 (d, 1 H, J = 16.8 Hz), 6.8 (dd, 1 H, J = 16.8 Hz 
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and 10 Hz); 13C NMR (50 MHz, CDCl3): characteristic peaks for PEG were observed. 
Two characteristic peaks for carbon atoms of vinyl sulfone was observed at δ = 126.68, 
137.99; HRMS (APCI): m/z (M+H) calculated for C28H55+1N3O12S: 690.3483; found: 
690.3469. 
1-Azido-35-(2-(vinylsulfonyl)ethoxy)-3n1053-pentatricontaoxaheptahectane (6b): 
To a solution of Azido-dPEG®36-alcohol (50 mg, 0.03 mmol) in anhydrous THF (1 mL), 
divinyl sulfone (36 mg, 0.3 mmol) was added with stirring, followed by the addition of 
potassium t-butoxide (4 mg, 0.035 mmol). The reaction was monitored by thin layer 
chromatography (TLC). Within one hour, the starting material was consumed and a less 
polar spot observed on the TLC plate. The reaction mixture was filtered, concentrated, 
and purified in a silica gel column by flash chromatography using 0-4% gradient of 
methanol in dichloromethane. The product 6b was separated as a white solid (33 mg, 
61%). FTIR (cm-1):1104 (S=O symmetric stretch), 1315 (S=O asymmetric stretch), 1600 
(C=C stretch), 2100 (N=N=N stretch), 3060 and 3100 (sp2 C-H stretch); 1H NMR (400 
MHz, CDCl3): δ = 3.26 (t, 2 H, J = 5.6 Hz), 3.39 (t, 2 H, J = 5.6 Hz), 3.5 - 3.7 (m, 142 H), 
3.9 (t, 2 H, J = 5.6 Hz), 6.09 (d, 1 H, J = 10 Hz), 6.39 (d, 1 H, J = 16.4 Hz), 6.82 (dd, 1 H, 
J = 10 Hz and 16.4 Hz); 13C NMR (50 MHz, CDCl3): characteristic peaks for PEG were 
observed. Two characteristic peaks for carbon atoms of vinyl sulfone was observed at δ = 
128.7, 137.9; MALDI-MS: m/z (M-H+Na) calculated for C76H151-1N3O38SNa: 
1769.0651; found: 1769.2117. 
Reactions of DNA Aptamers with molecular linkers (5) 
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A solution (20 μL, 10 mM) of Thrombin-binding DNA aptamer 5’-
GGTTGGTGTGGTTGG with a disulfide linker at 3’-end (IDT code: 3ThioMC3-D) in 
0.1 M phosphate buffer (pH 8.0) was treated with TCEP (5 μL, 170 mM in 0.1 M TEAA 
buffer, pH 7.0). After 3 h, the reaction mixture was passed through a size-exclusion G-25 
column (GE Healthcare) to remove small thiol molecules. The G-25 column was 
prepared following the protocol described by the manufacturers. First, the storage buffer 
was removed by centrifugation (1 min, 735 x g). Then the column was rehydrated again 
with double distilled water, followed by centrifugation (1 min,735 x g). Finally, the 
reaction mixture was added to the column, followed by centrifugation (2 min, 735 x g). 
The eluted solution containing thiol-functionalized aptamers (~25 μL) was then added to 
a solution of PEG linker 6a in 0.1 M phosphate buffer, pH 8.0 (20 μL, 50 mM). The 
reaction was finished in three hours, monitored by MALDI-TOF mass spectrometry. The 
product D-1a was purified using reverse phase HPLC with a Zorbax Eclipse Plus C18 
column (4.6 x 150 mm, particle size 5 μm) with a gradient of 0% to 70% over a period of 
25 mins (solvent A: a 0.1 M TEAA buffer, pH 7.0; solvent B: acetonitrile). The product 
has retention time of 17.4 min (with ~95% conversion). MALDI-TOF Mass: m/z (M+H) 
calculated for D-1a: 5570.51; found: 5571.63. After collecting the product using HPLC, 
the fraction was lyophilized to get the pure product. 
D-1b was synthesized in the same way and purified by HPLC with retention time of 17.1 
min (with conversion ~89%). MALDI-MS: m/z (M + H) calculated for D-1b: 6649.23; 
found: 6650.37. After HPLC purification, the collected fraction was lyophilized. 
Reaction of cyclo-RGD with molecular linkers (P-1b) 
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A solution of cyclo(RGDfC) (4 mM , 10 μL ) in a phosphate buffer (0.1 M, pH 8.0) is 
mixed with 6b (4 mM, 10 μL) dissolved in phosphate buffer (0.1 M, pH 8.0). The 
reaction was stirred for three hours at room temperature, monitored by MALDI mass 
spectrometry for its completion. The conversion was 99.5%, determined by HPLC 
analysis. The product was purified by HPLC using a Zorbax Eclipse Plus C18 column 
(4.6 x 150 mm, particle size 5 μm) under a gradient of 20% to 70% over a period of 25 
mins (Solvent A: 0.1% trifluoroacetic acid in de-ionized water; Solvent B: 0.09% 
trifluoroacetic acid in 80:20 acetonitrile: De-ionized Water; injection volume: 
14 μL), monitored with a UV detector at a wavelength of 230 nm. The conjugate P-1b 
was eluted out at retention time of 17 min. MALDI-MS: m/z (M+H) calculated for P-1b: 
2325.72; found: 2325.81. P-1a was prepared in the same way as did P-1b, purified by 
RP-HPLC, and characterized by MALDI-MS. MALDI-MS: m/z (M + H) calculated for 
P-1a: 1268.57; found: 1268.49. The conversion of peptide to its conjugate was 
quantitative. Both P-1a and P-1b fractions were lyophilized after HPLC purification. 
General Procedure for Attaching Affinity Molecules to AFM Tips. AFM tips (a batch 
of four or five) were first immersed in ethanol for 5 min, dried with ultrapure argon, and 
then treated with ultraviolet ozone in a Boekel UV cleaner for 15 min and oxygen plasma 
(medium power) in a Harrick Plasma Cleaner for 2 min. These tips were immediately 
placed in a Petri dish, to which an aqueous solution of compound 3 (50 mM) was added. 
After 1 h, the tips were taken out, rinsed with water thrice, and dried gently with nitrogen. 
In a humid surrounding, the cyclooctyne functionalized tips were placed in a Petri dish, 
and a solution of D-1a (50 μM, 20 μL) in 1X PBS buffer (pH 7.4) was added to cover all 
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the tips. The tips were incubated at room temperature for 1 h and then were rinsed thrice 
with the same buffer and used immediately. Other conjugates including D-1b, P-1a, and 
P-1b were also attached to the AFM tips under the exactly same conditions. 
Immobilization of Proteins on Mica Substrates. Freshly cleaved mica sheets (1.5 × 2.0 
cm2) were immersed in an aqueous solution of APS (50 mM). After 1 h, the mica sheets 
were taken out and rinsed thoroughly with water thrice. In a humid surrounding, an 
aqueous solution of glutaraldehyde (1 mM, 200 μL) was added on the APS mica sheet. 
After 10 min, the mica substrates were rinsed with water thrice, and then a solution of 
protein in a 1X PBS buffer (3 μL) was placed on each sheet, incubated for 1 h, and rinsed 
with the 1X PBS buffer thrice. In general, protein concentrations were made around 10 
ng/μL for force measurements and 0.05 ng/μL for recognition imaging. It should be noted 
that the integrin we used was a lyophilized product from a solution containing 0.26 
mg/mL α5β1, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl2, 0.2% Triton X-100, 
which was reconstituted by dissolving it in 1× PBS buffer. 
AFM Experimental Setup. An Agilent AFM 5500 (with inverted light microscope) 
system was used for the AFM experiments. Both force measurement and recognition 
imaging were carried out in 1X PBS buffer (pH 7.4). For force measurements, Veeco 
probes (Bruker, SiN tips) were used, having a force constant 0.05 N/m and a gold back 
coating, and the loading rate was 25 000 pN/s. For recognition imaging, magnetic 
cantilevers were used in AC (MAC) mode operation. Tips from NanoWorld were made 
of silicon and had a length of 125 μm, width 35 μm, and thickness 800 nm with force 
constant value of 0.14 N/m. The back sides of these tips were coated with 1 nm Ti/40 nm 
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Ni. They have a remarkably low spread in force constant (a few percentage) and give 
stable MacMode operation in even quite reactive solution. Also, Olympus tips (silicon 
nitride, a force constant 0.08 N/m) were functionalized and used for few recognition 
experiments. Each image was taken by scanning a 1 × 1μm2 area. 
For a blocking experiment, a protein solution (50 μL, 0.01 ng/μL in 1X PBS buffer, pH 
7.4) was added to the flow cell, and the surface was imaged again. In general, a 15−20 
min waiting time is needed to effectively block the tip. The blocking for force 
measurements proceeded in the same way. 
2.2.4. Conclusion.  
    We have developed a new scheme to attach affinity molecules to AFM tips for force 
spectroscopy and recognition imaging, based on two orthogonal click chemistries: 
catalyst free azide−alkyne cycloaddition and thiol-vinyl sulfone Michael addition. 
All the reactions can be carried out in aqueous solutions without the use of organic 
solvents. We synthesized two new reagents for this implementation. The first one is an 
APS derivative of cyclooctyne for introduction of a chemically reactive group to AFM 
tips. The silatrane chemistry allows for the formation of a uniform monolayer in aqueous 
solution, which is particularly useful when the chemical is not volatile and the vapor 
deposition would not work. The operation is more convenient compared to the vapor 
deposition technique and the resulting surface is highly reproducible. The second one is a 
class of heterobifunctional linkers with a form of “azido-PEG-vinyl sulfone”. Our data 
show that it works for both AFM based force measurement and recognition imaging. The 
attachment process is easy to follow since there are no special requirements for the 
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chemical reactions. With an increasing number of affinity oligonucleotides and peptides, 
more and more proteins will be detected with these synthetic materials. Incorporating 
thiol to peptides and oligonucleotides has become a routine process in custom synthesis. 
Hence, our attachment method should be applicable to a broad range of affinity 
molecules. 
2.3 Interactions of a Dipeptide with Universal Reader ICA on a Gold Substrate 
2.3.1. Introduction 
    We used a scanning tunneling microscope (STM), operated in buffered aqueous 
solution, to create a tunnel gap set to a reproducible distance by controlling the gap 
conductance, collecting useful signals up to 25 kHz in frequency. Palladium probes, 
partially insulated with polyethylene, and Pd substrates86, functionalized with the 
recognition molecule, 4(5)-(2-mercaptoethyl)-1H-imidazole-2-carboxamide (ICA), were 
used as electrodes87. We found that a tunnel current of 4 pA at a bias of 0.5 V produced 
Recognition Tunneling (RT) signals from all but two of the 20 naturally occurring amino 
acids, while phosphate-buffer controls were almost free of signals. This is surprising 
considering the fact that the reader molecule was designed to interact with DNA bases. 88 
Hence, we studied the binding of a dipeptide with the universal reader ICA with AFM 
force spectroscopy. 
2.3.2. Results and discussion 
We have studied the interactions of a dipeptide Cys-Gly with ICA on a single molecule 
level by means of Force Spectroscopy. The ICA was bound to a gold-coated mica surface 
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through its thiolated linker. The dipeptide was attached to AFM tips through the azido-
(CH2CH2O)36-vinyl sulfone linker discussed earlier.
60 
 
Scheme 2.3.1. Attachment of Cys-Gly and hexanethiol to vinylsulfone linker and 
attachment of ICA reader to Gold coated mica substrate.  
    As shown in Scheme 2.3.1, the peptide was first reacted with the linker, yielding a 
conjugate (1) containing an azide at its end, a functional group that was used for attaching 
the dipeptide to AFM tips through a alkyne-azide click reaction.60 Inspection of the 
structure in scheme 2.3.1 suggests that the dipeptide could be capable of forming 3 or 
more hydrogen bonds (the primary amine will be protonated and the carboxylate 
deprotonated at neutral pH). 
     Meanwhile, a control molecule (2) containing an alkane chain at its end was 
synthesized by reacting the same linker with hexanethiol, which should have not have 
hydrogen bonding interactions with ICA. 
    An AFM tip functionalized with the dipeptide 1 was brought down to contact a surface 
coated with ICA and then retracted back, and force-distance curves were recorded. In 
each experiment, we collected one thousand five hundred curves. About 10% of these 
1 
2 
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showed evidence of an event involving stretching of the PEG linker. Of this subset, we 
retained only those curves that fitted a WLC extension curve14 with a contour length of 
15±3 nm and for which the baseline force had returned close to 0 pN after the peak owing 
to non-specific interactions. An example of a force curve satisfying these criteria is 
shown in Figure S14a. We took over 500 force curves with the control molecule (2 is 
scheme 1) and none shown of these controls evidence of specific binding with all 
adhesion gone by 10 nm extension. We also measured the interactions of the dipeptide 
(1) with a bare gold surface finding no force curves in which the PEG tether was fully 
stretched. 
    Figure S14b shows a histogram of bond-breaking forces obtained from curves like 
those in Figure S14a using a probe of force constant 0.05 N/m (SiN probes from Veeco 
Probes) and a retraction speed of 700 nm/s. 
 
Figure23. Force spectroscopy of the glycine-ICA interaction. (a) Force curve showing a 
specific bond-rupture event consistent with stretching of the PEG linker of contour length 
15 nm (blue dashed curve is a fit to the WLC model). (b) Histogram of the distribution of 
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bond-rupture forces for a retraction speed of 700 nm/s and a force constant of 0.05 N/m. 
The red solid line is a calculated distribution for two hydrogen bonds using parameter 
values from Fuhrmann et al.89 
    Using the data presented in Fuhrmann et al.89, the modal breaking force for a complex 
involving 2 hydrogen bonds is about 22 pN, and this is consistent with the data shown in 
this histogram. More specifically, taking the force barrier, fB = 1/α, to be 5.8 pN (using 
the value for γ=1 from Fuhrmann et al.89), the calculated distribution90 is shown by the 
solid line. Clearly many of the events are consistent with two hydrogen bonds between 
the glycine and the ICA monolayer, though events at both lower and higher forces 
indicate that other bonding motifs are possible (and expected, given the structure of the 
peptide as discussed above). 
2.3.3. Experimental details: 
Synthesis of the dipeptide conjugate (1). To a solution of azido-(CH2CH2O)36-vinyl 
sulfone (50 μL, 1.0 mM) in pH 8 phosphate buffer was added a solution of the dipeptide 
(50 μL, 20 mM) in pH 8 phosphate buffer. The reaction was stirred for 3hrs at room 
temperature, followed by RP-HPLC purification using a Zorbax C18 column on an 
Agilent 1100 HPLC equipped with an ELSD detector under a gradient of 10 to 80% 
Methanol in a 10 mM TEAA buffer (pH 7.0) over a period of 25 mins. The retention time 
of the desired product was 12.6 mins. The collected solution was lyophilized and 
characterized by MALDI-MS on a Voyager MALDI-TOF instrument. MS: m/z (M+H) 
calculated for C29H59+1N5O15S: 1948.28; found: 1948.01. 
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Synthesis of the control molecule (2). To a solution of azido-(CH2CH2O)36-vinyl 
sulfone (50 μL, 1.0 mM) in DMSO was added a solution of hexanethiol (50 μL, 20 mM) 
in DMSO and triethylamine (1 μL). The reaction was stirred for 3 hrs at room 
temperature, followed by RP-HPLC purification using a Zorbax C18 column on an 
Agilent 1100 HPLC equipped with an ELSD detector under of gradient of 10 to 80% 
Methanol in a 10 mM TEAA buffer (pH7.0) over a period of 25 mins. The retention time 
of the desired product was 19.8mins. The collected solution was lyophilized and 
characterized by MALDI-MS on a Voyager MALDI-TOF instrument. MS: m/z (M+H) 
calculated for C30H63+1N3O12S: 1888.31; found: 1888.03 
Attachment. Both dipeptide conjugate 1 and control 2 were attached to AFM tips 
(Veeco probes, Bruker, SiN tips, force constant 0.05 N/m) by an azide-alkyne click 
reaction using N-(3-(silatranyl)propyl)-2-(cyclooct-2-yn-1-yloxy)acetamide as an 
anchoring molecule in a two-step protocol as discussed earlier. 
Functionalization of Gold substrates. Gold-coated mica substrates (Au(111), 2.4 x 
1.6 cm2, Agilent Technologies) were immersed in a solution of ICA (0.1 mM) in 
absolute ethanol for 1day, followed by rinsing with ethanol and water, and used 
immediately for AFM measurement 
AFM force measurement and data analysis. The force measurements were carried out 
at a loading rate of 35 nN/s on an Agilent 5500 AFM using functionalized tips against the 
ICA functionalized Gold substrates. Control experiments were performed using tips 
functionalized with the dipeptide conjugate 1 against the bare Gold substrate and tips 
functionalized with the control molecule 2 against the ICA coated Gold substrate. All the 
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experiments were carried out in 1X PBS buffer, pH 7.4. The force spectra were recorded 
using Agilent Picoview software. 
2.3.4. Conclusion.  
    This experiment convincingly proves that a dipeptide attached to an AFM tip 
interacts with universal reader ICA. Hence it is highly expected that ICA would be 
able to interact with amino acids in an STM tunnel gap. The AFM experiment also 
demonstrates that very weak unbinding forces between a functionalized tip and the 
substrate can be measured using our chemistry to functionalize AFM tips. 
2.4. A Three-Arm Scaffold Carrying Affinity Molecules for Multiplex 
Recognition Imaging by Atomic Force Microscopy 
2.4.1. Introduction 
One can conceive of using the recognition imaging for detection of low-abundance 
proteins in a biological sample. Compared to fluorescence microscopy, however, the 
AFM based recognition imaging lacks a multiplex capacity to detect multiple analytes in 
a single test. Wang et al. attempted to address the multiplexing issue by functionalizing 
AFM tips with an equimolar mixture of two types of antibodies.91 This approach attaches 
the antibody molecules to the apex of an AFM tip completely by random chance. As a 
result, it only showed marginal success in the multiplex recognition imaging. The 
challenge has been how to tether two different affinity molecules to the AFM tip so that 
they can interact with their respective cognates with an equal probability. In the present 
study, we have developed a “recognition head” built on a three-arm linker that can carry 
affinity molecules and be connected to AFM tips for the multiplex recognition imaging 
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(mRI). As illustrated in Figure 1, when such a recognition head tethered to an AFM tip 
scans across a surface covered with proteins, the two affinity moieties are bought to 
contact with each of these individual molecules, which generates a recognition image to 
localize each of cognate proteins through the specific affinity interactions. To identify 
each of these proteins, one of the affinity moieties in the recognition head will be 
blocked, for example, with its cognate protein for a second scan over the same area. This 
would allow us to distinguish between two different proteins. Here, we report on 
synthesis of the recognition heads, their attachment to AFM tips, and implementation in 
detecting proteins. 
 
Figure 24. AFM tip functionalized with a recognition head containing two affinity 
molecules through a three arm linker. 
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2.4.2. Results and discussion 
Three-Arm Linker. We devised a C3-symmetrical linking molecule with azide 
functional groups at its ends (Ar3, Scheme 2.4.1) as a scaffold for construction of the 
recognition heads. Although heterotrifunctional linkers are advantageous for orthogonal 
bioconjugation,92,93 a homotrifunctional linker has the advantages of simpler synthesis 
and reduced structural variations at the linkage sites. We synthesized Ar3 by reacting 
1,3,5-triethynylbenzene (1) with 1-azido-37-(4-iodophenyl)-3n36
3-
dodecaoxaheptatriacontane under the Sonogashira coupling conditions (Reaction 1.1).94 
The product was obtained with a 35% yield, purified with column chromatography, and 
fully characterized with NMR, and mass spectrometry (see Experimental Section). The 
three-arm linker Ar3 features a rigid hard core flanked by three flexible poly(ethylene 
glycol) (PEG) chains with azido functions at their ends for the bioconjugation and 
attachment. In general, the recognition imaging requires a fairly long linker to tether the 
affinity molecule to an AFM tip so that it can keep the AFM tip away from a substrate for 
most of the measurement period. A PEG chain with 12−18 units of ethylene glycol meets 
this requirement and suffices to accurately locate the binding sites of analyte molecules 
immobilized on a surface.85,95 This is why it is commonly used as a flexible linker for the 
recognition imaging. By contrast, we designed the three-arm linker differently by placing 
a sizable hard core in the center of the linker, attempting to reduce the flexible portion of 
the linker to a minimum without affecting the binding efficiency of the affinity moieties. 
Thus, the increased rigidity should reduce the loss in conformational and rotational 
entropy caused by binding to the target molecule(s) immobilized on the surface, which is 
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thermodynamically unfavorable.96 We adapted tris(phenylethynyl)benzene due to its 
large π conjugating structure to increase the rigidity of the linker as well as to avoid the 
possible collision between two affinity moieties by pointing them in opposite directions. 
Meanwhile, we have to ensure that the linker has sufficient solubility for the following 
bioconjugating reactions. We found that three 12-unit PEG chains were needed to give 
the linker the solubility of ∼0.1 mg/μL in aqueous solution when they were attached to 
the 4′ position of tris(phenylethynyl)benzene hard core (see Scheme 2.4.1). 
 
Scheme 2.4.1. Reaction for synthesis of Three-Arm Linker 
Conjugating Affinity Molecules to the Three-Arm Linker. We have constructed two 
recognition heads: RH-1, which is composed of anti-VEGF97 and anti-TNFα98 DNA 
aptamers (Figure 23A), and RH-2, which is composed of antithrombin aptamer80,99 and 
cyclo-RGDfK that binds to integrin receptors100 (Figure 23B), for the mRI studies. These 
aptamers have nanomolar affinities to their respective cognate proteins (Kd: 403.6 nM for 
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anti-VEGF,97 7.0 nM for anti-TNFα,98 240 ± 16 for anti-thrombin101), and the cyclo-
RGDfK binds to both intergrin α5β1 and αvβ3 with IC50 of 133 and 2.6 nM.102 
 
Figure 25. Chemical structures of Recognition heads 
Previously, we demonstrated that both cyclo-RGDfK and antithrombin aptamer could 
effectively generate recognition images with their cognate proteins when they were 
attached to AFM tips through a linear linker.60 Compared to antibodies, these affinity 
molecules are much smaller in size and chemically more robust, making them ideal 
candidates for construction of the recognition heads. To attach them to the three-arm 
linker, each of these custom-synthesized DNA aptamers was synthesized to bear a 
dodecylamino chain at their 5′-ends and the cyclopeptide contained a lysine residue. We 
converted them into aza-dibenzocyclooctyne (ADIBO) derivatives, named as ADIBO-
anti-VEGF, ADIBO-anti-TNFα, ADIBO-anti-Thrombin, and ADIBO-cyclo-RGD, by 
reacting with ADIBO-Nhydroxysuccinimidyl ester (see experimental section). The 
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ADIBO group spontaneously reacts with azide in aqueous solution, known as catalyst-
free click addition, which has allowed us to readily construct the recognition heads, as 
discussed below. We synthesized RH-1 with a route described in Figure 25. 
 
Figure 26. Synthesis of RH-1 
First, ADIBO-anti-VEGF reacted with Ar3 with a ratio of 1:2 in water (Reaction 2.1 in 
Figure 25). Reverse Phase (RP) HPLC analysis indicated that the reaction was finished in 
less than 1min, forming a monoaddition product A-1 with a high yield (>99%, Figure 
25B,i). We attribute the high selectivity to the solvent condition. In water, the negatively 
charges of an aptamer is much less shielded than in the buffered solution. Once one 
aptamer was attached to Ar3, the second addition of an aptamer stalled because of the 
electrostatic repulsion. A-1 was separated by HPLC and characterized as a pure product 
(see details in RH-1 of Experimental Section). It reacted with ADIBO-anti-TNFα (0.5 
equiv) in a triethylammonium acetate (TEAA) buffer (Reaction 2.2), resulting in the 
desired product RH-1 with a yield of ∼90% plus ∼10% of a bis(anti-TNFα) byproduct 
(Figure 25B, ii). Beforehand, we had attempted to carry out the reaction in water, and 
  
49 
found out that it went so slowly that no significant amount of product was observed even 
after 1 h. We hypothesized that the charge repulsion prevented A-1 from reacting with 
the same negatively charged reactant ADIBO-anti-TNFα. A TEAA buffer was used for 
the reaction to shield the negative charges, giving us a fairly good selectivity (∼90%) as 
mentioned above. RH-1 were separated by HPLC and characterized by MALDI mass 
spectrometer (see RH-1 in Experimental Section). RH-2 was synthesized by first reacting 
with peptide (ADIBO-cyclo-RGD) and then with aptamer ADIBO-antithrombin (Figure 
26A). This route offered advantages over the other way around with better control over 
the addition of the affinity molecules to Ar3 and more easily separating the final 
products. As shown in Figure 26, the reaction 3.1 was well controlled at a monoaddition 
stage by applying an excess amount of Ar3 to it (Ar3 to ADIBO-cyclo-RGD = 5:1). RP 
HPLC analysis indicated that ADIBO-cyclo-RGD was consumed soon after these two 
starting materials were mixed in water, yielding two products with a ratio of 86% to 14% 
(Figure 26B, i). These two products could readily be separated by HPLC. MALDI mass 
spectrometry identified that the major product resulted from monoaddition of ADIBO-
cyclo-RGD to Ar3 (A-2) and the minor product from the bis-addition. The following 
reaction was carried in water as well with a 25% excess of A-2 (Reaction 3.2). As shown 
in Figure 4B, ii, most of ADIBO-anti-thrombin was consumed in a minute. Extending the 
reaction to 30 min resulted in RH-2 with a 93% yield and a small amount of bis-addition 
byproduct (∼7%), which was separated by HPLC and characterized with MALDI mass 
spectrometry (see RH-2 in Experimetnal Section for details).  
  
50 
 
Figure 27. Synthesis of RH-2 
In this section, we describe facile methods to synthesize a DNA−organic molecule−DNA 
(or peptide) conjugate with a high yield and high reaction rate by means of click 
chemistry. Lee et al. reported a three day reaction of amino functionalized DNA with N-
hydroxysuccinimide (NHS) ester of 1,3,5-benzenetricarboxylic acid in DMSO/water, 
which only produced the desired product with a 10% yield.103 They attribute such a low 
yield to a consequence of steric hindrance and electrostatic repulsion between DNA 
molecules. Interestingly, Seela and co-workers reported that a DNA containing a 
tripropargylamino side chain readily reacted with azido functionalized oligonucleotides 
in the presence of a copper catalyst.104 Since the reaction was accelerated significantly in 
the presence of benzoic acid, we believe that reduction of the electrostatic repulsion may 
be a key factor for production of DNA−organic molecule−DNA hybrids with high yields. 
We have found utilization of Mg2+ to shield the negative charges of the DNA backbone 
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could produce the same effects as benzoic acid did (data not shown). Here, we 
demonstrate that the addition of charged molecules to the three-arm linker can be well 
controlled simply by changing the solvent. It should be noted that the ADIBO-azide 
reaction normally results in a regioisomeric mixture of the triazole connection. In our 
case, the affinity molecules were connected to Ar3 through either N-1 or N-3 of the 
triazole ring (see Figure 24). However, we have not observed that the subtle difference in 
structure exerts any significant effects on the recognition imaging (vide infra). 
Attaching Recognition Heads to AFM Tips. We have previously developed a method 
to attach affinity molecules through a linear linker to AFM tips using a catalyst-free click 
reaction.60 We adopted this method for attachment of these recognition heads. As 
illustrated in Figure 27, Ni-coated silicon tips (from Nanoworld particularly for 
recognition imaging) were first functionalized with a cyclooctyne function by reacting 
with a cyclooctyne derivative of 1-(3′-amino)propylsilatrane (3)60 in aqueous solution, 
and then reacted with a recognition head in buffered solution (see Experimental Section 
for details).  
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Figure 28. Attaching Recognition heads to AFM tips. 
Since there is presently no effective way to characterize the covalent bonding on AFM 
tips, we attempted to provide evidence that there was a chemical attachment by means of 
force measurement. We measured the interacting forces of RH-1 attached to a silicon 
nitride tip with one of its cognate proteins VEGF. From the force−distance curves, we 
observe that the binding rupture occurred at a distance around 14 nm, which corresponds 
to the length of the recognition head plus other carbon chains, and the unbinding force 
was around 65 pN with a loading rate of 60 nN/s (Figure 29). This shows the existence of 
a recognition head on the AFM tip.  
 
Figure 29. (A) Force−distance curve of a RH-1 functionalized tip retracting from a 
VEGF immobilized mica surface; (B) Distance histogram of the unbinding events; (C) 
Force histogram of RH-1 unbinding from VEGF immobilized on the mica surface. 
Multiplex Recognition Imaging (mRI) of Proteins. We adapted a procedure reported 
by Wang et al.91 to perform mRI experiments, which involves three sequential steps: (1) 
imaging a protein surface by driving an AFM tip carrying an recognition head across a 2 
× 2 μm2 area and recording the simultaneous topographic and recognition images; (2) 
injecting a first blocking solution to the liquid flow cell, and repeating the step 1 in the 
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same area; (3) injecting a second blocking solution to the cell and repeating the step 1 
again. We first tested RH-1 on imaging its cognate proteins VEGF and TNFα. A 1:1 
mixture of these two proteins in a phosphate buffer (pH 7.4) was deposited on a mica 
surface functionalized with glutaraldehyde. We have routinely used glutaraldehyde as a 
cross-linker to immobilize proteins for recognition imaging.84 Using RH-1, we were able 
to generate recognition images from the VEGF-TNFα surface (Figure 30). 
 
Figure 30. Topographic (A) and recognition (B) image of a VEGF and TNF-α mixture; 
(C) anti-VEGF aptamer-blocked recognition image; (D) both aptamers-blocked 
recognition image. Imaging size: 0.75 × 0.75 μm and all of recognition images have the 
same amplitude scale. 
 
In general, the AFM based recognition imaging produces not only a recognition image, in 
which the recognition sites appear as dark spots, but also a topographic image 
simultaneously, in which each feature appears as white. From the topographic image 
(Figure 29 A), we can immediately notice a complex surface morphology, features of 
which vary in sizes and shapes. This may reflect differences in structures between VEGF 
and TNFα as well as effects of the surface chemistry, assuming that each feature 
represents either an individual protein or a protein aggregate. First, the crystal structures 
show that VEGF (PDB ID: 2VPF) has approximate dimensions of 6.5 × 3.5 × 2.0 nm, 
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flatter than TNFα (∼5.9 ×5.5 × 4.8 nm, PDB ID: 1TNF). Also, both VEGF and TNFα 
have pI values very close to 7.0 (7.5 for VEGF and 7.4 for TNFα, calculated from 
http://protcalc.sourceforge.net), so they may easily form aggregates around neutral pH. 
Second, since glutaraldehyde mainly reacts with lysine residues (11 for VEGF and 5 for 
TNFα) and the N-terminal amines, the immobilization chemistry may result in each 
protein molecule displaying on the surface with different orientations. All of these factors 
may contribute to the complicated surface morphology of the VEGF and TNFα mixture, 
making it impossible to distinguish between these two proteins from the topography. 
However, the recognition image (Figure 29 B) seems more resolvable. This is because 
the recognition imaging only “sees” the binding site, a small portion of protein. As an 
example, the feature in the green circle in Figure 29 A could be an aggregate of multiple 
proteins according to its size (W × L × H = ∼38 × 80× 1.6 nm). By examining the 
recognition image (the green circle in Figure 29 B), we can tell that the feature possibly 
consists of two protein molecules. The following blocking experiments allowed us to 
unambiguously assign the spot 1 as TNFα and spot 2 as VEGF (to be discussed in the 
next paragraph). Furthermore, we counted those spots both in Figure 29 A,B, and found 
that there were about 80% features in Figure 29 A recognized as protein by RH-1. This 
recognition rate is consistent with our previous results from using AFM tips 
functionalized with one type of affinity reagent.60 Since the purity of the protein materials 
in this study was greater than 95%, we believe that the immobilization chemistry placed a 
statistical limit on the recognition efficiency because glutaraldehyde randomly reacted 
with amines of proteins, rendering some of the binding sites blocked by the mica surface 
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and not reachable by the affinity moieties. Following the first scan, a VEGF solution was 
injected into the flow cell to block the anti-VEGF aptamer attached to the AFM tip, and 
the same surface area was scanned again to acquire a second recognition image (Figure 
29 C). By comparing with Figure 29 B, we can clearly see that the spot 1 remained and 
spot 2 disappeared in Figure 29 C. As a result, we could assign these two spots to the 
corresponding proteins. Presumably, all of the spots in Figure 29 C resulted from the anti-
TNFα aptamer interacting with the TNFα protein. To confirm this, a TNFα solution was 
injected into the flow cell, which resulted in an image with no recognition (Figure 29 D). 
The above results demonstrate that the two aptamers of RH-1 can specifically interact 
with their respective cognate proteins, subject to no interference from each other. To 
further confirm the specificity of RH-1, we scanned a 1:1 mixture of thrombin and 
streptavidin deposited on the mica surface, which resulted in no recognition image. 
Therefore, we assign those spots in Figure 29 C as the protein TNFα with high 
confidence. By superimposing the image C on B we created a superimposed recognition 
image from which we identified all of protein spots in the first recognition image (Figure 
30 A). In figure 30 A black topped-by-green spots correspond to the TNFα protein and 
the rest of black spots to the VEGF protein. By counting the green and black spots we 
determined that the ratio of VEGF to TNFα on the surface is about 0.9:1, close to that in 
the parent solution (1:1). To further test RH-1, we deposited a solution of VEGF and 
TNF-α mixed in a 5:1 ratio on the mica surface, and found that the recognition efficiency 
of RH-1 was still about 80%. In the same fashion as described above, a superimposed 
image was created for identification of individual proteins (Figure 31 B). Figure 31 B 
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shows the superimposed image, from which we can clearly see there are less green spots, 
compared to Figure 30 A. The ratio of VEGF to TNFα on the surface was determined as 
∼5:1 by counting those black and green spots in Figure 31 B. 
 
Figure 31. Superimposed recognition images in (A) VEGF and TNF-α (1:1 in solution) 
deposited on the mica surface, and (B) from a mixture of VEGF and TNF-α (5:1 in 
solution) deposited on the mica surface. Black topped-by-green spot, TNF-α protein; 
black, VEGF protein. Imaging size: 0.75 × 0.75 μm. 
We further tested RH-1 on a more complex mixture consisting of four proteins VEGF, 
TNF-α, thrombin, and streptavidin. First, we examined the specificity of mRI by 
performing a series of control experiments: using a RH-1 tip to scan a mica surface 
modified with a 1:1 mixture of thrombin and streptavidin, which only yielded a 
topographic image (Figure 32 A), but no recognition image (Figure 32 A′); using a bare 
AFM tip and a tip functionalized with the cyclooctyne 3 to scan a surface modified with a 
VEGF and TNFα mixture, which again only yielded topographic images (Figure 32 B 
and 32 C), and no recognition images (Figure 32 B′ and 32 C′). When scanning a mica 
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surface on which a mixed solution of four proteins (VEGF/TNFα/thrombin/streptavidin = 
1:1:2:1.5) was deposited, we were able to obtain both topographic and recognition images 
(Figure 32 D, D′) using a tip functionalized with RH-1.  
 
Figure 32. AFM images with different tips and substrates. Top panel: topographic image 
of (A) a tip functionalized with RH-1 against a 1:1 mixture of thrombin and streptavidin 
deposited on mica; (B) a bare tip against a 1:1 mixture of VEGF and TNF-α deposited on 
mica, (C) a tip functionalized with cyclooctyne against a 1:1 mixture of VEGF and TNF-
α deposited on mica, (D) a tip functionalized with RH-1 against a mixture of VEGF, 
TNF-α, thrombin and streptavidin deposited on mica. Bottom panel: recognition image of 
A′ relating to topographic image A, B′ to B, C′ to C, and D′ to D. All of recognition 
images have the same amplitude scale. Imaging size: 0.75 × 0.75 μm. 
There were 26% of proteins in Figure 831 D recognized, a 72% recognition rate which is 
slightly smaller than what we have had from the mixture of two proteins. The recognition 
specificity was confirmed by blocking experiments. In the same manner as described 
above, the ratio of VEGF/TNFα on the surface was determined as 1.5:1, higher than that 
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in their parent solution. Nonetheless, this is the first demonstration that the recognition 
imaging is able to detect multiple proteins in such a complex mixture. 
    Next, we tested RH-2 for mRI with a 1:1 mixed solution of thrombin and integrin α5β1 
deposited on the mica surface. Similarly, RH-2 yielded a recognition image with 80% of 
protein in the topographic image recognized (Figure 33 A, B). From the superimposed 
recogntion image (Figure 33 E) generated by overlapping the image C over B in Figure 
33, we determined the ratio of thrombin to integrin α5β1 on the surface as 1:0.9. Note 
that those pale yellow spots in the recognition image C and D in Figure 33 may be caused 
by the spillover of amplitude from topographic image to recognition image.57  
 
Figure 33. Topographic (A) and recognition (B) image of a thrombin and integrin α5β1 
mixture; (C) recognition image from blocking anti-thrombin aptamer; (D) recognition 
image from blocking both aptamer and RGD; (E) superimposed recognition image of C 
over B. Black topped-by-green spot, integrin; black, thrombin. Imaging size: 2 × 2 μm 
and all of recognition images have the same amplitude scale. 
Further, we also notice that the measured ratios in all the cases varied from those in the 
sample solutions more or less. To fully understand the discrepancies, thus, further studies 
are needed on molecular immobilization and on thermodynamic and kinetic effects on 
interactions of the affinity molecule tethered to an AFM tip with its cognate protein 
immobilized on the surface. 
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2.4.3. Experimental details 
General Information. All reagents and solvents were purchased from commercial 
suppliers (Sigma-Aldrich, Alfa Aesar, Fluka, TCI America) and used as received unless 
otherwise noted. ADIBO-N-hydroxysuccinimidyl ester was purchased from Click 
Chemistry Tools. All experiments requiring anhydrous conditions were performed in 
flame-dried glassware under nitrogen atmosphere. Reactions were monitored by thin 
layer chromatography (TLC) using silica gel precoated on glass plates (EMD Millipore). 
1H NMR and 13C NMR spectra were recorded on Varian INOVA 400 (400 MHz) 
spectrometer at 25 °C. Chemical shifts (δ) are given in parts per million (ppm) and 
referenced to the residual solvent peak (CDCl3, δH = 7.26 ppm; CD3OD, δH = 3.31 ppm; 
DMSO-d6, δH = 2.50 ppm). Coupling constants (J) are expressed in hertz (Hz) and the 
values are rounded to the nearest 0.1 Hz. Splitting patterns are reported as follows: br, 
broad; s, singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q, 
quartet and m, multiplet. High-resolution mass spectra (HRMS) were acquired at the 
Arizona State University CLAS High Resolution Mass Spectrometry Facility. Flash 
chromatography was performed in an automated flash chromatography system 
(CombiFlash Rf, Teledyne Isco, Inc.) with silica gel columns (60−120 mesh). RP-HPLC 
analysis and separation were performed with either a Zorbax C-18 column or with 
Zorbax 300 SB-C18 column (4.6 × 150 mm, particle size 5 μm) in an Agilent 1100 
HPLC equipped with UV monitor and fraction collector. VEGF (Vascular Endothelial 
Growth Factor, Human Recombinant,95%), a lyophilized product from a concentrated (1 
mg/mL) solution with no additives, TNFα (Tumor Necrosis Factor-Alpha, Human 
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Recombinant, 95%), a lyophilized product from 1 mg of TNF-α Human contain 20 mM 
PB, pH-7.2, and 100 mM NaCl were purchased from ProSpec; Integrin from Yo proteins 
AB (Sweden), a lyophilized product from a solution containing 0.26 mg/mL α5β1, 20 
mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl2, 0.2% Triton X-100. They were 
reconstituted by dissolving in water before use according to manufacture 
recommendation. Human α-thrombin and streptavidin were purchased from AbCam and 
Alfa Aesar, respectively. Recognition imaging was performed on Agilent’s MacMode 
AFM equipped with a PicoTREC system, and silicon tips purchased from NanoWorld. 
The cantilever was made having length of 125 μm, width of 35 μm, and thickness of 800 
nm with a force constant of 0.14 N/m. Its backside was coated with 1 nm Ti/40 nm Ni. 
Synthesis of 1-Azido-35-((4-iodobenzyl)oxy)-3n333-undecaoxapentatriacontane (2). 
The compound 1 A was synthesized following a route described in Scheme 2.4.2. The 
starting material was synthesized following protocol outlined in section 2.4.1. 
 
                1 A                                         1 B                                                2     
Scheme 2.4.2. Synthesis of compound 2. 
Special note on nomenclature: To avoid excessive use of a long series of numbers, the 
mathematical shorthand for expressing arithmetic progressions is used to denote the 
positions of oxygen atoms in the elongated PEG chains, as proposed by Hii and 
coworkers.73 
1-Azido-35-tosyloxy-3n333-undecaoxapentatriacontane (1 B). Tosyl Chloride (TsCl, 
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1.67g, 8.76 mmol) was added to a solution of 35-azido-3n333-undecaoxapentatriacontan-
1-ol (1 A, 2.5g, 4.38 mmol) and triethylamine (Et3N, 3 mL, 21.53 mmol) in anhydrous 
dichloromethane (DCM, 15 mL) under nitrogen. The reaction mixture was stirred at room 
temperature for 12 h, and then the solvent was removed by rotary evaporation. The 
residue was purified by silica gel column chromatography using a gradient of 3.5% 
methanol in dichloromethane over 4 h, giving compound 1 B as a colorless liquid (2.86 g, 
90% yield). 1H NMR (400 MHz, CDCl3): δ 2.97 (s, 3 H); 3.37 (t, 2 H, J = 5.2 Hz); 3.58-
3.3.69 (m, 44 H); 4.51 (t, 2 H, J = 4.8 Hz); 7.35 (d, 2H, J = 8 Hz); 7.79 (d, 2 H, J = 8 Hz); 
13C NMR (100MHz, CDCl3): δ 144.71, 132.92, 129.76, 127.85, 70.61-70.40, 69.92, 
69.21, 68.54, 50.57, 21.54, HRMS m/z (M+H): found 726.3472; calcd. for 
C31H55+1N3O14S 726.3483. 
1-Azido-35-((4-iodobenzyl)oxy)-3n333-undecaoxapentatriacontane (2). Potassium-
tertbutoxide (KOtBu, 482.5 mg, 4.30 mmol) was added to a solution of 1 B (2 g, 2.76 
mmol) and p-iodobenzylalcohol (0.84 g, 3.59 mmol) in anhydrous tetrahydrofuran (THF, 
4 mL) under nitrogen. The mixture was stirred at room temperature for 2 h, cooled down 
in an ice bath, and quenched by the addition of methanol (2 mL). The solvent was 
removed by rotary evaporation, and the residue was separated by silica gel column 
chromatography using a gradient of 3.5% methanol in dichloromethane over 4 h. 
Compound 2 was obtained as yellowish oil (1.85 g, 85%). 1H NMR (400 MHz, CDCl3): δ 
3.30 (t, 2H, J = 5.2 Hz); 3.57-3.58 (m, 46H); 4.42 (s, 2H); 7.02 (d, 2H, J = 8Hz); 7.57 (d, 
2H, J = 8.4 Hz); 13C NMR (100MHz, CDCl3): δ 138.00, 137.26, 129.45, 92.84, 72.32, 
70.54-70.40, 69.91, 69.50, 50.54; HRMS m/z (M+Na): found 810.2642, 
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calcd. for C31H54N3O12I+Na 810.2650. 
Synthesis of 1,3,5-Tris{[4-(1-azido-3n363-
dodecoxaheptatriacontyl)phenyl]ethynyl}benzene (Ar3). 1,3,5-Triethynylbenzene (1, 
62 mg, 0.41 mmol) and compound 2 (1.0 g, 1.27 mmol) were mixed in anhydrous 
tetrahydrofuran (7.5 mL) and triethylamine (7.5 mL) under nitrogen. The solution was 
degassed by slowly bubbling nitrogen for 10 min, to which 
bis(triphenylphosphine)palladium(II)dichloride (14.4 mg, 0.02 mmol) and copper(I) 
iodide (3.9 mg, 0.02 mmol) were added. The mixture was refluxed for 48 h, cooled to 
room temperature, and filtered. The solvent was removed by rotary evaporation. The 
residue was separated by silica gel column chromatography with a gradient of 4% 
methanol in dichloromethane over 4 h. The product Ar3 was obtained as a yellowish oil 
(307 mg, 35%). 1H NMR (400 MHz, CDCl3): δ 3.36 (t, J = 5.2 Hz, 6H, N3CH2); 
3.62−3.68 (m, 138H, OCH2CH2O); 4.58 (s, 6H, ArCH2); 7.33 (d, J = 8.4 Hz, 6H, ArH); 
7.49 (d, J = 8.4 Hz, 6H, ArH); 7.62 (s, 3H, ArH). 13C NMR (100 MHz, CDCl3): δ = 
139.03, 133.97, 131.68, 127.58, 124.02, 121.90, 90.43, 87.75, 72.79, 70.68−70.56, 70.01, 
69.66, 50.67. MALDI-MS (M + Na): found m/z 2152.51; calcd for C105H165N9O36Na 
2152.46. 
General procedure for functionalization of DNA aptamers with ADIBO. 
 
Scheme 2.4.3. ADIBO functionalization of DNA aptamers 
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ADIBO derivatives of aptamers were synthesized by a reaction described in Scheme 
2.4.3. In detail, a stock solution of 5’-dodecylamine-modified DNA aptamer in water (1.0 
mM, 10 μL) was diluted with a 100 mM phosphate buffer (30 μL), pH 8.5. The final pH 
measured 8.4. To the DNA aptamer solution, a DMSO solution of ADIBO-NHS ester (10 
mM, 80 μL) was added. The mixed solution was vortexed for 15 min at room 
temperature, and then lyophilized. The solid residue was re-dissolved in water (120 μL) 
and centrifuged. The supernatant that contained the product was separated from the 
ADIBO precipitate. RP-HPLC analysis indicated that the aptamer was quantitatively 
converted to its ADIBO derivative. The product was purified using RP HPLC with an 
eluting system composed of (A) TEAA buffer (10 mM, pH 7) and (B) acetonitrile. The 
mobile phase started at 90% A and 10% B, linearly increasing to 60% B in 25 min, 
followed by increasing B to 100% in 5 min. The retention times for the ADIBO 
derivative of anti-Thrombin aptamer (ADIBO-anti-Thrombin) was 11.6 min, for the 
ADIBO derivative of anti-VEGF aptamer (ADIBO-anti-VEGF) was 11.0 min, for the 
ADIBO derivative of anti- TNFα aptamer (ADIBO-anti-TNFα) was 10.1 min. The 
collected fractions of the product were lyophilized, reanalyzed with HPLC and 
characterized by MALDI-mass spectrometry: 
ADIBO-anti-Thrombin MALDI m/z: found 5307.3; calcd. for C183H230+1N59O99P15: 
5305.7 
ADIBO-anti-VEGF MALDI m/z: found 8272.8; calcd. for C276H348+1N101O151P25: 8271.7 
ADIBO-anti-TNFα MALDI m/z: found: 8364.4; calculated for C278H348+1N105O152P25: 
8367.7 
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3. ADIBO derivative of cyclo-RGD. A solution of cyclo-RGDfK peptide in water (1.0 
mM, 10 μL) was diluted with a 100 mM phosphate buffer (30 μL), pH 8.5. To the 
solution, a DMSO solution of ADIBO-NHS ester (80 μL, 10 mM) was added. The mixed 
solution was vortexed for 15 min at room temperature, and then lyophilized. The residue 
was re-dissolved in water (50 μL) and centrifuged. The supernatant was separated from 
the ADIBO precipitate. RP-HPLC analysis indicated that the peptide was quantitatively 
converted to its ADIBO derivative. The product was purified using RP HPLC with an 
eluting system composed of (A) 0.1% TFA in DI water and (B) 0.09% TFA in 80:20 
acetonitrile:water. The retention time of the product in RP HPLC was 14.6 min with a 
mobile phase started at 80% eluent A and 20% eluent B, linearly increasing to 70% B in 
25 min, followed by increasing B to 100% in 5 min.The ADIBO-RGD derivative was 
characterized by MALDI-mass m/z: found 919.8; calcd. for C48H58+1N10O9: 920.0 
RH-1. A solution of Ar3 in water (400 μM, 30 μL) was added to a solution of ADIBO-
anti-VEGF in water (200 μM, 30 μL). After 1 min, the reaction was checked by injecting 
1 μL of the reaction solution into RP-HPLC. The HPLC analysis indicated that the 
aptamer was fully consumed and a new peak appeared at a retention time of 18.0 min in 
the chromatogram (eluent A, 10 mM TEAA buffer, pH 7; eluent B, acetonitrile; under a 
linear gradient of increasing B from 10 to 70% in 25 min). The monoaddition product A-
1 was separated using HPLC with the same eluting system. MALDI-MS (M + H): 
found m/z 10401.8; calcd for C381H513+1N110O187P25 10402.2. Next, A-1 (150 μM, 15 μL) 
was mixed with ADIBO-anti-TNFα (75 μM, 15 μL) in a TEAA buffer (50 mM, pH 7). 
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The reaction was kept at room temperature for 1 h and separated using the same HPLC 
conditions for the monoaddition product. RH-1 has retention time of 14.5 min. 
MALDI-MS (M + H): found m/z 18768.6; calcd for C659H861+1N215O339P50 18766.7. 
RH-2. A solution of Ar3 in water (1.0 mM, 30 μL) was added to a solution of ADIBO-
cycloRGD in water (0.2 mM, 30 μL). The solution was checked by HPLC after 1 min. 
RP-HPLC analysis indicated that the peptide was completely consumed and a new peak 
appeared at retention time of 25.1 min in the chromatogram under the same elution 
conditions as the one for RH-1. The monoaddition product A-2 was separated by HPLC. 
MALDI-MS (M + H): found m/z 3050.2; calcd for C153H223+1N19O45 3049.5. A-2 (100 
μM, 15 μL) was mixed with ADIBO-anti-thrombin (80 μM, 15 μL) in water. The reaction 
was stirred at room temperature for 30 min. RH-2 was separated by RP HPLC under the 
same conditions mentioned above. The product has retention time of 15.1 min. MALDI-
MS (M + H): found m/z 8349.2; calcd for C336H453+1N78O144P15 8354.2. 
Attaching Recognition Heads to AFM Tips. AFM tips (a batch of four) were first 
soaked in ethanol in a Petri dish for 5 min, dried with nitrogen, and then treated with 
oxygen plasma (medium power) for 2 min in a Harrick Plasma Cleaner and then with 
ultraviolet-ozone in a Boekel UV cleaner for 5 min. These tips were immersed in an 
aqueous solution of N-(3-(silatranyl)propyl)-2-(cyclooct-2-yn-1-yloxy)acetamide (3, 50 
mM) in a Petri dish. After 1 h, the tips were taken out, rinsed with water thrice, and dried 
gently with a nitrogen flow. In a humid surrounding, the cyclooctyne-functionalized tips 
were placed in a Petri dish and a recognition head solution (10 μM, 20 μL) in 1× PBS 
buffer (pH 7.4) was added to cover all the tips. After 1 h, the tips were rinsed thrice with 
  
66 
the same buffer and used immediately for AFM measurements. However, the probes can 
be stored in 1× PBS buffer (pH 7.4) at 4 °C at least for 2 days. Normally, there were 
about 50% of them that worked effectively for recognition experiments in every batch of 
4 to 5 functionalized tips 
Protein Immobilization. First, a mica surface was functionalized following an 
APTES/glutaraldehyde procedure developed in our laboratory.84 Then, a protein solution 
(3 μL) was added to the glutaraldehyde-coated mica in a humid chamber, incubated for 
30 min, rinsed with a 1× PBS buffer (pH 7.4) three times, and immediately placed on the 
AFM stage for use. The following solutions were used for the study: 
A mixed solution of VEGF and TNF-α (0.35 nM each) 
A mixed solution of VEGF (0.48 nM) and TNF-α (0.1 nM) 
A mixed solution of VEGF (0.1 nM), TNF-α (0.1 nM), thrombin (0.2 nM) and 
streptavidin (0.15 nM) 
A mixed solution of thrombin (0.28 nM) and streptavidin (0.28 nM) 
A mixed solution of integrin α5β1 and thrombin (0.3 nM each). 
Multiplex Recognition Imaging. AFM images were acquired by PicoTrec using 
magnetically (Ni) coated cantilevers in AC (MAC) mode operation with AC frequency at 
8 kHz, set point of 4 V, and a scan speed of 2.2 μm/s. For imaging with RH-1 
functionalized tips, the protein deposited on the mica surface was covered with 1× PBS 
buffer (pH 7.4, 600 μL). After initial scanning, a first blocking solution (0.3 nM VEGF in 
1× PBS buffer, pH 7.4, 50 μL) was injected to the flow cell, incubated for 10 min, and 
followed by scanning in the same area. A second blocking solution (0.6 nM TNF-α in 1× 
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PBS buffer, pH 7.4, 50 μL) was injected into the flow cell, incubated for 10 min, 
followed by scanning in the same area. Four samples were examined with RH-1: two 
mixed solutions of VEGF and TNFα, respectively, with 1:1 and 5:1 molar ratios, a mixed 
solution consisting of VEGF, TNF, thrombin, and streptavidin with a ratio of 1:1:2:1.5, 
and a mixed solution of thrombin and streptavidin with a 1:1 molar ratio. For imaging 
with RH-2 functionalized tips, a mixed solution of thrombin and integrin α5β1 with a 1:1 
molar ratio was deposited on the mica surface and covered with 1× PBS buffer containing 
1 mM MnCl2 (pH 7.4, 600 μL). The experiment was carried out in the same way as 
described above, and two blocking solutions, integrin (0.2 nM in 1× PBS buffer, pH 7.4, 
50 μL) and thrombin (0.15 nM in 1× PBS buffer, pH 7.4, 50 μL), were used sequentially. 
Note: in some cases, injection of additional blocking solution (50 μL) was needed in 
order to achieve the effective blocking. 
Force measurement. Force spectroscopy experiments were carried out in PBS 1x buffer 
(pH 7.4). For force measurements, Veeco probes (Bruker, SiN) tips were used having a 
force constant of 0.15 N/m and a gold black coating, and the loading rate was 60 nN/s. 
Vegf protein (270 nM) was immobilized on glutaraldehyde functionalized mica. Initially 
800 force-distance curves were collected with RH-1 functionalized tips against Vegf 
following which tips were blocked with VEGF protein (2.7 nM, 50 μL in 1X PBS buffer, 
pH 7.4) and 500 more force-distance curves were collected. The force curves were 
analyzed in PicoView, and the specific unbinding forces (between 10-16 nm) were 
plotted in a histogram form and fitted into the Gaussian function using software 
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OriginPro 2015, in which the Levenberg–Marquardt algorithm was used for the curve 
fitting. 
Data Analysis. All of the topographic and recognition images, and force spectra were 
recorded using Agilent PicoView software. Topography images presented in the 
manuscript were processed in Gwyddion software. Those spots were counted as proteins 
with a threshold around 1 nm. The recognition images were analyzed using Picoview. 
Background noises of the recognition images were scaled about −50 mV. Typical 
recognition events were observed to have intensity between −100 mV and −1.2 V. To 
determine the recognition rates, topography and recognition images were saved as image 
files and superimposed in Adobe Photoshop. The numbers of unrecognized and 
recognized proteins were manually counted from the superimposed image. In the same 
fashion, individual proteins were identified by image superimposing and manually 
counting. 
2.4.4. Summary 
In the present study, we have developed a new approach to using AFM for multiplex 
recognition imaging. With a recognition head attached to an AFM tip, we were able to 
scan multiple proteins immobilized on a surface. The recognition head was designed 
based on a hypothesis that two affinity molecules connected by a well-spaced linker 
should interact with their respective cognate molecules effectively. Our studies have 
shown that the affinity molecules tethered to the three-arm linker worked independently 
and equally, which allowed us not only to identify two different proteins but also to 
relatively quantitate them by counting. 
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                                                            CHAPTER 3 
MOLECULAR TROJAN HORSE TO TARGET ADVANCED WEST NILE                 
VIRUS INFECTION 
3.1. Introduction 
    The West Nile virus (WNV), a mosquito born flavivirus, is a neurotropic, enveloped 
virus with a single-stranded, positive polarity, 11-kilobase RNA genome and has 
circulated in Africa, Asia, the Middle East, and Europe before entering USA in 1999 and 
had spread over all of continental USA by 2000.105-107 Numerous cases have been 
diagnosed over the past decade and many infected people remain undiagnosed. Currently 
more than 2000 cases get reported to the CDC each year in the USA. However, in spite of 
considerable efforts an effective therapeutic is yet to be discovered. 
   The WNV viral lifecycle starts by attachment of the virus to an yet to be identified 
cellular receptor108 following which the virus undergoes endosomal fusion and structural 
rearrangement of E glycoproteins and insertion of the hydrophobic fusion loop into the 
vesicular membrane.108,109 In absence of data for human pathogenesis, animal models 
have aided our understanding about West Nile virus infection and disease.108 Upon 
transmission from infected mosquitoes the virus is believed to replicate within 
keratinocytes and dendritic cells following which dendritic cell migration to lymph nodes 
leads to viral replication and transmission into peripheral organs following which the 
final deadly stage involves neuroinvasion and infection of the CNS 108,110 where it leads 
to severe malaise and death. Humoral response is extremely crucial against West Nile 
infection and disease.111,112 Most neutralizing antibodies bind to viral surface E proteins 
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thus preventing receptor attachment and virus internalization.112-116 Most potent 
neutralizing antibodies so far studied has been found to bind with the DIII domain of the 
E-glycoprotein.108,112 Of these the E16 is the most potent and well characterized 
neutralizing antibody.109,117 Humanized murine E16 and humanized plant E16 (hE16) has 
shown high efficacy and is shown to protect mice even four days after infection.107,117 
However once the infection gets transmitted to the CNS, the effectivity of E16 gets 
limited as the antibody is unable to cross the Blood Brain Barrier (BBB).107 
    Hence, we devised a new structure based on a molecular Trojan horse approach21-23 for 
delivery of hE16 or monoclonal antibodies in general into the CNS. 
 
 
 
 
 
 
 
 
Figure 34. Structure of Molecular Trojan Horse 
    The central structure of the scaffold consists of a rigid hydrophobic core surrounded 
with multiple hydrophilic chains to promote the scaffold’s solubility in water and tether 
multiple functional groups at the ends. Chemically the design balances hydrophobicity 
against hydrophilicity and flexibility against rigidity. In the present study, we have used 
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Angiopep-2, which targets the low-density lipoprotein receptor-related protein (LRP) and 
is reported to mediate transport of ligands across the BBB. 118-123 
    Our conjugate shows superior efficacy in cell binding and neutralization assays and we 
are currently testing conjugates for survival studies in vivo. 
3.2. Results and Discussion 
Three Arm Linker. We devised a C3-symmetrical linking molecule with azide 
functional groups at its ends (Ar3, Scheme 2.4.1) by reaction between 1,3,5-
triethynylbenzene (1) with 1-azido-37-(4-iodophenyl)-3n36
3-dodecaoxaheptatriacontane 
as reported earlier124 as a scaffold for construction of a bis-angiopep-2 linker. The 
scaffold consists of the rigid hydrophobic core and is attached multiple hydrophilic 
chains resulting in a solubility of 0.1 mg per mL of water. 
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Figure 35. Structure of Three Arm Linker Ar3 
Conjugating Angiopep-2 to Ar3. The Angiopep-2 is a 19 amino acid peptide. It was 
custom synthesized with propargylglycine amino acid at the C-terminus. The propargyl 
glycine is capable of reacting with an azide by copper catalyzed click chemistry.125 
Hence, we synthesized the bis-Angiopep-2 conjugate of Ar3 (compound CJ1) by mixing 
three molar equivalents of Angiopep-2 with Ar3 in presence of copper catalyst (see 
experimental section for details). A water soluble ligand tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) 125 was employed for the reaction. HPLC 
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Time 
(min) 
analysis showed that the Angiopep-2 was totally consumed after 1 hour and bis-
Angiopep-2 conjugate was obtained in about 42% selectivity. 
 
  
Figure 36.  HPLC chromatogram of reaction between Ar3 and Angiopep-2 to prepare 
bis-Angiopep-2 (ANGII) conjugate. 
Oxidation of hE16. Plant based hE16 was expressed and assembled in plants as per 
literature protocol.107 Each heavy chain of the antibodies had N-linked glycans containing 
a fucose unit that can be oxidized with Sodium periodate. The E16 antibodies were buffer 
exchanged in 100 mM Sodium Actetate buffer (pH 5.5) following which the antibodies 
were oxidized using Sodium periodate in pH 5.5 Sodium Acetate buffer (see 
CJ1 
ANGII 
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experimental section for details) as per literature protocol.126 The efficiency of the 
oxidation was checked by reacting the oxidized antibody with excess of hydrazine 
functionalized Lucifer yellow dye. A mixture of unoxidized antibody with Lucifer yellow 
and acetate buffer mixed with Lucifer yellow were used as controls for the experiment. 
Fluorescence spectroscopy after purification (figure 37) confirmed the conjugation of 
Lucifer yellow to oxidized antibody. 
 
Scheme 3.1. Oxidation of hE16 with Sodium Periodate. 
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Figure 37. Fluorescence spectroscopy of Lucifer yellow conjugates. 
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BCN functionalization of E16.  
(1R,8S,9R)- bicyclo[6.1.0]non-4-yn-9-ylmethyl(4-nitrophenyl)carbonate (BCN-NHS) 
was reacted with O,O'-[oxybis(2,1-ethanediyloxy-2,1 ethanediyl)]bis(hydroxylamine) to 
obtain compound 2 (scheme 3.2) (see experimental section for synthetic details). 
 
Scheme 3.2. Synthesis of compound 2 
The oxidized antibody is reacted with compound 2 in pH 5.5 Sodium Acetate buffer 
following which it is purified to obtain BCN functionalized antibody (BCN-E16) 
(scheme 3.3) 
 
 
Scheme 3.3. BCN modification of hE16. 
The BCN functionalization was confirmed by reacting BCN-E16 with two different 
Alexa Fluor 488 functionalized azides (3 and 4) (see experimental section for synthesis). 
Size exclusion chromatography showed absorbance at 495 nm indicating the attachment 
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of Alexa Fluor 488 on the antibody. On the contrary even when the unmodified antibody 
is mixed with 30 fold molar excess of Alexa Fluor there is no increase in absorbance at 
495 nm indicating that the Alexa Fluor is only getting attached to the BCN-E16 by 
reaction of the azide with the BCN. UV-vis analysis of the purified Alexa Fluor 488 
conjugates from a set of similar experiments demonstrated 1.3-1.6 dyes per antibody for 
conjugate with 3 and 1-1.4 dyes per antibody for conjugate with 4. 
 
 
Figure 38. Reaction of BCN functionalized hE16 with Alexa Fluor azide 3. 
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3 
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Figure 39. Reaction of BCN functionalized hE16 with Alexa Fluor azide 4. 
Conjugation of CJ1 to BCN-E16. Following this we proceeded to conjugate the BCN-
E16 with CJ1. 6 molar equivalents of CJI was mixed with mixed 1 molar equivalent of 
BCN-E16 in pH 4 acetate buffer and allowed to stir at room temperature for 1.5 hours 
following which they were purified by Size Exclusion Chromatography. For the 
conjugation reactions with BCN-E16 we observed that the best yields were obtained at 
pH 4. Reaction at pH 7.4 produced loss of yield due to precipitation probably due to 
aggregation of the conjugates in the concentrated mixture due to higher extent of 
labelling at neutral pH. We observed that CJ1 has a local maxima at 310 nm and hence, 
the BCN functionalized antibody after reaction with CJ1 showed an increased absorbance 
at 310 nm. We see two major peaks in the HPLC chromatogram of the E16-CJ1 
4 
Time (min) 
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conjugates. From GEL electrophoresis we concluded that the peak 1 with a retention time 
around 5.7 min is probably a mixture of antibody aggregates and highly labelled antibody 
conjugates while the peak 2 is a mixture of labelled and unlabeled antibody. The 
molecular weight of CJ1 appeared to be too small to cause a change in retention time in 
the HPLC chromatogram. A mixture of unmodified antibody and CJ1 was used as a 
control for this experiment. There was no increase in absorbance at 310 nm for the 
unmodified antibody indicating no reaction between CJ1 and the unmodified E16. After 
purification with size exclusion chromatography the UV-vis spectra for the E16-CJ1 
conjugate shows a local maxima at 310 nm indicating the conjugation of E16 to CJ1. The 
UV-vis spectra for the unmodified antibody after purification with size exclusion 
chromatography does not show a local maxima at 310 nm indicating that CJ1 has not got 
conjugated to the unmodified antibody. 
 
 
A 
 
B 
A’ B’ 
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Figure 40. Conjugation of BCN-E16 with CJ1. A. HPLC chromatogram, A’. UV spectra 
of purified conjugate, B. HPLC chromatogram of unmodified E16 mixed with CJ1, B’ 
UV spectra after purification. 
Following purification MALDI-MS of the samples were obtained. The M/2 peak for the 
hE16 came around 74 kD while the M/2 peak for the E16-CJ1 comes around 77.5 kD. 
 
Figure 41. Maldi-MS of E16 (orange) and E16-CJ1 (blue). 
Synthesis of linear linker-Angiopep-2 conjugate. An Angiopep-2 functionalized peg-
24 linear linker, CJ2 was prepared by copper catalyzed click reaction between 
propargylglycine functionalized Angiopep-2 with peg-24-diazide (ccompound 5). CJ2 
was then conjugated to the BCN-E16 in a similar manner as the three arm linker to 
synthesize E16-CJ2. 
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Scheme 3.4. Syntheis of E16-CJ2 
SPRi studies. Analysis of antibody-antigen binding was carried out using Plexera 
Bioscience Surface Plasmon Resonance Imaging (SPRi) setup. In brief, the SPRi setup 
allows to build multiple sensitive spots using the same setup and a CCD camera is 
employed to ecord the intensity of the reflected light at a fixed angle and wavelength.127 
Rational signal sampling can be made from reproducible selection of sensing areas on the 
Gold biochip.128 These sensing areas are known as Region of Interest (ROI). The SPRi 
technology allows to analyze multiple sensing areas (ROI) for a particular analyte and 
hence allows to analyze multiple analytes in the same experiment and also allows to look 
at the reproducibilty of the results. 
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Figure 42. Scheme of SPRi apparatus. Reproduced with permission from reference (125) 
copyright 2011 Elsevier. 
To perform the SPRi experiment thiolated protein A was immobilized on a Gold 
biosensor chip. The antibodies (E16 and E16-CJ1) were immobilized offline on the 
protein A functionalized chip. Multiple spots for each analyte are made by handspotting 
the samples on the biosensor chip with the assistance of a perforated PDMS membrane. 
Following this the biosensor chip is mounted on the SPRi instrument and two glycerol 
injections are made to optimize the signals and convert them to response unit (RU). 
Following this the antigen (DIII, 200 nM)  is flown over the antibody functionalized 
biosensensor. The DIII is injected for 2 min at a flow rate of 5 µL/s following which 
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buffer is passed at a flow rate of 2 µL/s.  Figure 43 gives the schematic diagram of the 
SPRi experiment. 
 
Figure 43. Scheme of SPRi experiment. 
Figure 44 gives typical SPR curve for the experiment. Several ROIs for interaction 
between protein A and DIII is taken as control for this experiment. Figure 44 shows a 
typical SPRi signal for interaction of DIII with E16 and E16-CJ1. 
 
 
  
 
 
 
Figure 44. Typical SPRi curve for A. DIII binding to E16 (curve A) and DIII binding to 
E16-CJ1 (curve B) and B. DIII binding to protein A. 
A B 
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The results obtained from analyzing data from multiple ROIs is as follows: 
 Sample        ka (M
-1s-1)               kd (s
-1)        KD (M
-1) 
 E16     3.8 +/- 0.7 x 105        2.0 +/- 0.3 x 10-3    4.95 +/- 1.6 x 10-9 
 E16-CJ1     3.5 +/- 0.4 x 105        4.0 +/- 1.0 x 10-3   10.01 +/- 3.4 x 10-9 
 
Table 3.1. Kinetic analysis of data obtained from multiple ROI during SPRi 
measurement 
Antigen binding activity. Antigen binding activity was tested by studying binding 
activity between E16-CJ1 with yeast displaying DIII on their surface. Flow cytometric 
analysis showed higher fluorescence intensity for E16-CJ1 compared to basal 
fluorescence. 
 
Cell binding assay. U87 cells were utilized to study cell-binding using both E16-CJ1 and 
E16-CJ2. Flow cytometric analysis indicated higher binding of E16-CJ1 to the U87 cells 
compared to E16-CJ2. 
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Figure 45. Antigen binding activity and cell binding activity of conjugates 
Neutralizing activity. Neutralization potential of E16-CJ2 using WNV-reporter virus 
particles using literature based protocol. The E16-CJ2 showed similar efficacy as 
unmodified E16. 
3.3. Experimental details. 
General Information 
All reagents and solvents were purchased from commercial suppliers (Sigma-Aldrich, 
Alfa Assar, Fluka, and TCI America) and used as received unless otherwise noted. Alexa 
Fluor 488 alkyne was purchased from ThermoFisher Scientific. Angiopep-2 was custom 
synthesized from CPC Scientific. Slide-A-Lyzer dialysis cassettes were purchased 
ANGII
ANGII
ANGII
ANGII
ANGII
ANGII
ANGII
ANGII
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ThermoFisher Scientific. Centrifugal filter units were purchased from EMD Millipore. 
All experiments requiring anhydrous conditions were performed in flame-dried glassware 
under nitrogen atmosphere. Reactions were monitored by thin layer chromatography 
(TLC) using silica gel precoated on glass plates (EMD Millipore). 1H NMR and 13C 
NMR spectra were recorded on Varian INOVA 400 (400 MHz) spectrometer at 25 °C. 
Chemical shifts (δ) are given in parts per million (ppm) and referenced to the residual 
solvent peak (CDCl3, δH = 7.26 ppm; CD3OD, δH = 3.31 ppm; DMSO-d6, δH = 2.50 
ppm). Coupling constants (J) are expressed in hertz (Hz) and the values are rounded to 
the nearest 0.1 Hz. Splitting patterns are reported as follows: br, broad; s, singlet; d, 
doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q, quartet and m, 
multiplet. High-resolution mass spectra (HRMS) were acquired at the Arizona State 
University CLAS High Resolution Mass Spectrometry Facility. MALDI-MS was 
performed using a Bruker MALDI-MS instrument at ASU. SPRi analysis was performed 
by a PlexaArray HT instrument from Plexera Biosciences. Flash chromatography was 
performed in an automated flash chromatography system (CombiFlash Rf, Teledyne Isco, 
Inc.) with silica gel columns (60−120 mesh). RP-HPLC analysis and separation were 
performed with either a Zorbax C-18 column or with Zorbax 300 SB-C18 column (4.6 × 
150 mm, particle size 5 μm) in an Agilent 1100 HPLC equipped with UV monitor and 
fraction collector. Size Exclusion Chromatography was performed on the same 
instrument using a Biosep-SEC-s3000 column. 
Synthesis of CJ1. CJ1 was synthesized using a modified protocol reported by Finn and 
coworkers. In brief Ar3 (1.5 mM, 30 L) was mixed with propargylglycine 
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functionalized Angiopep-2 (4.5 mM, 30 L) followed by the addition of Phosphate 
buffer, pH 7 (30 L), a 1:5 mixture copper sulfate (40 mM) and THPTA (100 mM) (3 
L), Aminoguanidine Hydrochloride (200 mM, 10 L) and Sodium Ascorbate (200 mM, 
10 L) following which the reaction mixture is stirred at room temperature for 1 hour. 
HPLC monitoring showed the Angiopep-2 gets fully consumed after 1 hour. The bis-
Angiopep-2 conjugate was purified by reverse phase HPLC using a 300 SB-C18 column. 
The retention time of the product in RP HPLC was 16.7 min with a mobile phase started 
at 70% eluent A and 30% eluent B, linearly increasing to 90% B in 25 min, followed by 
increasing B to 100% in 5 min. CJ1 was obatined in 42% selectivity. The sample was 
collected, lyophilized, redissolved in DI water and characterized by MALDI-MS: m/z 
(M+H) found. 6918.0 calcd. 6921.66 
Synthesis of compound 1 and 2. Compound 1 and 2 was synthesized as described in 
literature.129 
Synthesis of compound 5.   
Compound 5 was synthesized by reaction between compound 5A and compound 5B (see 
chapter 2 for synthesis of compound 5A and 5B). To a solution of compound 5A (1 g, 
1.75 mmol) in 2 mL anhyrous THF at 0C is added sodium hydride (51 mg, 2.13 mmol) 
and allowed to stir for 30 min following which compound 5B (1.4 mg, 1.93 mmol) 
dissolved in 2 mL anhydrous THF is slowly added to the reaction mixture at 0C. 
Following this, the reaction mixture is brought to room temperature and allowed to stir 
for 15 h. The completion of the reaction is monitored by TLC and the solvent is 
evaporated under vacuo and the reaction mixture is purified by silica gel column 
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chromatography under a gradient of 3.5% Methanol in DCM to obtain compound 5 as a 
colorless liquid. (1.38 g, 70% yield). 1H NMR (400 MHz, CDCl3): δ 3.37 (t, 4 H, J = 4.8 
Hz); 3.62-3.69 (m, 92 H); 13C NMR (100MHz, CDCl3): δ 70.67-70.54, 70.02, 50.65. 
MALDI-MS. m/z (M+H): found 1147.45; calcd. for C48H96N6O23Na 1148.28 
 
N3
O
H
12
N3
O
Ts
12
N3
O
23
N3
NaH, THF, rt, 15 h
5A 5B 5
70%
 
Scheme 3.5. Synthesis of compound 5. 
Synthesis of compound 3. Alexa Fluor 488 alkyne (2 mM, 20 L) was mixed with 
compound 5 (10 mM, 20 L) followed by the addition of Phosphate buffer, pH 7, 100 
mM (50 L), a 1:5 mixture copper sulfate (20 mM) and THPTA (50 mM) (1.5 L), 
Aminoguanidine Hydrochloride (100 mM, 5 L) and Sodium Ascorbate (100 mM, 5 L) 
following which the reaction mixture is stirred at room temperature for 1 hour. HPLC 
monitoring showed the Alexa Fluor 488 gets conjugated after 1 hour. The product was 
purified using RP HPLC with an eluting system composed of (A) 0.1% TFA in DI water 
and (B) 0.09% TFA in 80:20 acetonitrile: water. The retention time of the product in RP 
HPLC was 6.6 min with a mobile phase started at 80% eluent A and 20% eluent B, 
linearly increasing to 85% B in 25 min. The purified product was lyophilized and 
redissolved in DI water. MALDI-MS. m/z (M+H): found 1694.71; calcd. for 
C72H113+1N9O33S2 1697.82. 
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Synthesis of compound 4. Compound 4 is synthesized by following scheme 3.6 as 
illustrated below. 
 
Scheme 3.6. Synthesis of compound 4. 
Synthesis of 4a. Alexa Fluor 488 alkyne (2 mM, 20 L) was mixed with Ar3 (10 mM, 20 
L) followed by the addition of Phosphate buffer, pH 7, 100 mM (50 L), a 1:5 mixture 
copper sulfate (20 mM) and THPTA (50 mM) (1.5 L), Aminoguanidine Hydrochloride 
(100 mM, 5 L) and Sodium Ascorbate (100 mM, 5 L) following which the reaction 
mixture is stirred at room temperature for 1 hour. HPLC monitoring showed the Alexa 
Fluor 488 gets conjugated after 1 hour. The product was purified using RP HPLC with an 
eluting system composed of (A) 0.1% TFA in DI water and (B) 0.09% TFA in 80:20 
acetonitrile: water. The retention time of the product in RP HPLC was 16.9 min with a 
mobile phase started at 80% eluent A and 20% eluent B, linearly increasing to 85% B in 
25 min followed by increase to 100% B in 30 mins.. The purified product was lyophilized 
and redissolved in DI water to obtain compound 4a. MALDI-MS. m/z (M+H): found 
2698.38; calcd. for C129H182+1N12O46S2 2701.03. 
Synthesis of 4. Angiopep-2 alkyne (0.5 mM, 20 L) was mixed with 4a (0.75 mM, 20 
L) followed by the addition of Phosphate buffer, pH 7, 100 mM (50 L), a 1:5 mixture 
copper sulfate (20 mM) and THPTA (50 mM) (1.5 L), Aminoguanidine Hydrochloride 
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(100 mM, 5 L) and Sodium Ascorbate (100 mM, 5 L) following which the reaction 
mixture is stirred at room temperature for 1 hour. HPLC monitoring showed the 
Angiopep-2 gets conjugated after 30 min. The product was purified using RP HPLC with 
an eluting system composed of (A) 0.1% TFA in DI water and (B) 0.09% TFA in 80:20 
acetonitrile: water. The retention time of the product in RP HPLC was 16.9 min with a 
mobile phase started at 85% eluent A and 15% eluent B, linearly increasing to 70% B in 
25 min. The purified product was lyophilized and redissolved in DI water to obtain 
compound 4a. MALDI-MS. m/z (M+H): found 5093.6; calcd. 5096.6 
Oxidation of hE16. hE16 antibodies were buffer exchanged to pH 5.5 NaOAc buffer 
(100 mM) using 10kD Amicon ultracentrifeugal filters.  The antibodies are concentrated 
to about 15 mg/mL (100 M). 100 L Sodium periodate (20 mM) is mixed with 100 L 
of the hE16 in an amber colored effendorf tube at 4C and the reaction mixture is stirred 
for four hours at 4C. The reaction is quenched by addition of 10 L ethylene glycol at 
0C following which the mixture is purified by using 10kD Amicon ultracentrifeugal 
filters. The antibodies are kept in pH 5.5 NaOAc buffer (100 mM) for the next reaction. 
The efficiency of the reaction is tested by Lucifer yellow assay. To 100 L of the 
antibody solution (10 M) in pH 5.5 NaOAc buffer is added 10 L of 6-Amino-2,3- 
dihydro-1,3-dioxo-2-hydrazinocarbonylamino-1H-benz[d,e]isoquinoline-5,8-disulfonic 
acid dilithium salt (Lucifer yellow hydradine) solution (22 mM). The reaction mixture is 
stirred overnight. As controls, 100 L unmodified antibody solution (10 M) in pH 5.5 
NaOAc buffer and 100 L of pH 5.5 NaOAc buffer are mixed with 10 L of Lucifer 
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yellow hydrazine solution (22 mM) and stirred overnight at room temperature.  
Following this, the reaction mixtures are purified by10 kD Amicon ultracentrifeugal 
filters and the fluorescence intensity of the solutions are measured with a 
spectrofluoremeter. 
BCN functionalization of E16. 
100 µL of the oxidized hE16 antibody (100 µM) is mixed with 25 µL of 20 mM 
oxamine-BCN linker (compound 2) in pH 5.5 NaOAc buffer (100 mM) following which 
the reaction mixture is stirred overnight in an amber colored micro centrifuge tube. The 
reaction mixture is purified using Amicon ultracentrifugal 10 kD filters and the 
functionalized antibodies were buffer exchanged to pH 4 NaOAc buffer (100 mM). The 
attachment of the oxamine-BCN linker to the antibody was tested using the reaction 
between 15 µL of the BCN-conjugated antibody (40 µM) with 15 µL of Alexa Fluor-
azide (compound 3) (200 µM) in pH 4 NaOAc buffer (100 mM). The reaction mixture 
was stirred for 1.5 h at room temperature following which it was purified by Size 
Exclusion Chromatography using a Biosep-SEC-s3000 column. The purified conjugates 
are collected and concentrated using Amicon ultracentrifugal 100 kD filters following 
which the compounds are buffer exchanged to PBS pH 7.4 by dialyzing for 6 hours using 
slide-a-lyzer dialysis cassettes with 3.5 kD molecular weight cut-off (Thermo scientific). 
UV analysis indicated two Alexa Fluor molecules attached to each antibody. 
    To test the attachment further, 15 µL of the BCN-E16 (40 µM) was mixed with 15 µL 
of compound 4 (80 µM) in pH 4 NaOAc buffer (100 mM) and the reaction mixture was 
stirred for 1.5 h at room temperature following which it was injected to HPLC and 
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purified by Biosep-SEC-s3000 column. The purified conjugates are collected and 
concentrated using Amicon ultracentrifugal 100 kD filters following which the 
compounds are buffer exchanged to PBS pH 7.4 by dialyzing for 6 hours using slide-a-
lyzer dialysis cassettes with 3.5 kD molecular weight cut-off (Thermo scientific). UV 
analysis indicated two Alexa Fluor dyes per antibody. 
Synthesis of E16-CJ1. 100 µL of the BCN-E16 (40 µM) was mixed with 100 µL of CJ1 
(200 µM) in pH 4 NaOAc buffer (100 mM) and the reaction mixture was stirred for 1.5 h 
following which it was injected to HPLC and purified by Biosep-SEC-s3000 column 
using pH 3 Sodium Phosphate buffer (100 mM). The fractions from the HPLC are 
collected and concentrated using Amicon ultracentrifugal 100 kD filters following which 
the compounds are buffer exchanged to PBS pH 7.4 by dialyzing for 6 hours using slide-
a-lyzer dialysis cassettes with 3.5 kD molecular weight cut-off (Thermo scientific). 
Synthesis of CJ2. Propargylglycine functionalized Angipeptide-2 (2 mM, 20 L) was 
mixed with compound 5 (10 mM, 20 L) followed by the addition of Phosphate buffer, 
pH 7, 100 mM (50 L), a 1:5 mixture copper sulfate (20 mM) and THPTA (50 mM) (1.5 
L), Aminoguanidine Hydrochloride (100 mM, 5 L) and Sodium Ascorbate (100 mM, 5 
L) following which the reaction mixture is stirred at room temperature for 1 hour. 
HPLC monitoring showed the Angiopep-2 gets conjugated after 1 hour. The product was 
purified using RP HPLC with an eluting system composed of (A) 0.1% TFA in DI water 
and (B) 0.09% TFA in 80:20 acetonitrile: water. The retention time of the product in RP 
HPLC was 14.3 min with a mobile phase started at 85% eluent A and 15% eluent B, 
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linearly increasing to 75% B in 25 min. The purified product was lyophilized and 
redissolved in DI water. MALDI-MS. m/z (M+H): found 3518.6; calcd. 3521.9. 
Synthesis of E16-CJ2. 100 µL of the BCN-E16 (40 µM) was mixed with 100 µL of CJ2 
(200 µM) in pH 4 NaOAc buffer (100 mM) and the reaction mixture was stirred for 1.5 h 
following which it was injected to HPLC and purified by Biosep-SEC-s3000 column 
using pH 3 Sodium Phosphate buffer (100 mM). The fractions from the HPLC are 
collected and concentrated using Amicon ultracentrifugal 100 kD filters following which 
the compounds are buffer exchanged to PBS pH 7.4 by dialyzing for 6 hours using slide-
a-lyzer dialysis cassettes with 3.5 kD molecular weight cut-off (Thermo scientific). 
3.4. Summary. We have synthesized a bis-Angiopep-2 conjugate of hE16 antibody. The 
conjugate shows good efficacy in cell binding assays to U87 brain cells and binds to 
antigen displayed on yeast cell more strongly compared to the conjugate with mono-
Angiopep-2 linker. The conjugate also shows good efficacy in neutralizing WNV-
reporter virus particles. We are currently studying the efficacy of the conjugate is treating 
mice infected with WNV. 
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                                                             Chapter 4 
   SYNTHESIS OF MULTIVALENT CONSTRUCTS TO MIMIC ANTIBODIES 
4.1 Introduction 
While antibodies can specifically target pathogens, for example being used as “magic 
bullets” to treat cancers,130 they exhibit poor extravasation and limited tissue penetration 
due to their large size and complexity.131,132 In contrast, small molecule drugs can easily 
access intracellular disease targets, but they have notorious off-target toxicities and lack 
effectiveness to block protein-protein interactions.133 Can we create a new molecular 
entity that bears merits of both large and small drugs to overcome their shortcomings? 
Recently, McEnaney et al have demonstrated that an antibody analogy containing 
targeting and effector moieties, which only has approximately 5% of the molecular 
weight of an antibody, can selectively elicit immune response for cellular phagocytosis 
through bivalent interactions.134 This may open a new avenue of developing effective 
therapeutics by creating structural mimics of the antibody with small drug molecules. 
Hence, inspired by the structure of immunoglobulin G (IgG), we designed and 
synthesized small sized antibody mimics to enhance the ligand to receptor interaction. 
The two systems that we designed were: 
1. A Y shaped bis-biotin as a small sized structural mimic 
2. A tripod antibody to target glycoproteins of ebola virus. 
4.2. Synthesis of a Y-shaped Scaffold for building small-sized Antibody Mimics 
4.2.1. Introduction 
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In the present study, we have designed a Y-shaped scaffold composed of three arms, 
assuming that such a structure has a more favorable geometry for bivalent ligand binding 
to two separated binding sites of a receptor than a linear linker does. An antibody mimic 
can be constructed by attaching two ligands to the scaffold, leaving one of its arms for 
immobilization or attachment to monitor the ligand-to-receptor bivalent interactions by 
means of ensemble and single molecule methods. 
4.2.2. Results and discussion 
We have designed the Y-shaped ligand taking the following in consideration: (a) make 
the structure have sufficient flexibility so that its pendent ligands can bind to the receptor 
in much the same way as they are in the free state, (b) maximize the rigidity of the 
structure to reduce the possible loss in conformational entropy upon binding, and (c) 
avoid non-specific interactions of the scaffold with the receptor and other non-targeting 
molecules. For example, when DNA is used as a linker, it can interact with proteins 
through electrostatic attraction, which may become an entropically favorable process due 
to release of the counterions135-137 resulting in strong nonspecific binding. 
    To demonstrate the principle of design, we chose the biotin-streptavidin interaction as 
a model system because it has been well studied so high-resolution crystal structures of 
biotin-streptavidin complexes are available, allowing us to design details at an atomic 
level. We designed a Y-shaped bis-biotin (hereinafter referred to as y-Bisbiotin) ligand, 
based on a biotin-streptavidin crystal structure with a 0.95Å resolution.138 Streptavidin is 
a tetrameric molecule with 222 point group symmetry, each subunit bearing a biotin 
binding site.139 From the projection shown in Figure 46, three bound biotin molecules are 
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observable, indicating that a bi- or tri-valent ligand can readily access these binding sites 
simultaneously. This has been demonstrated by Taylor et al using trisbiotinylated 
oligonucleotides with the length of > 20 nucleotides to occupy three of streptavidin’s four 
biotin-binding sites.140 In the complex, the distances between the biotin molecules are 
measured ranging from 19 to 35 Å (Figure 46-B). Based on these data, we designed the 
y-Bisbiotin molecule with a rigid core of 3,5-bis(phenylethynyl)aniline with a width of 
~17 Å, which is connected to three flexible oligo[ethylene glycol] (OEG) linkers (Figure 
46-C). In the structure, two biotin molecules are respectively attached to those OEG 
linkers situated at the para positions of the phenyl ring 1 and 3, and an azido function to 
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Figure 46. A) A view of the crystal structure of a biotin-streptavidin complex, adopted 
from Protein Data Bank (PDB ID: 3RY2); (B) Distances between biotins in the complex, 
determined by measuring the distance between the ureido oxygen atoms, and between 
oxygen atoms of the carboxylates in the crystal structure; (C) Chemical structure of a y-
Bisbiotin ligand; (D) A DFT model of y-Bisbiotin, calculated by B3LYP in combination 
with a 6-31G* basis set in a vacuum using software Spartan’14. 
the OEG linker of the aniline fragment. The DFT (Density Functional Theory) 
calculation shows that the structure can display as a Y shape with its two biotins 
separated by a distance of about 34 Å (Figure 41-D), which matches the distance between 
biotin 1 and biotin 2 in the crystal structure (see Figure 41-B). In addition, the bivalent 
ligand shows a dyad axis of symmetry the same as those in the streptavidin-biotin 
complex. We designate the two branches connecting to biotins as Arm 1 and Arm 2, and 
the third one as the Stem (see Figure 41-D). The OEG linker with 6 ethylene glycol units 
should provide sufficient flexibility for the biotin ligands binding to streptavidin and 
solubility for y-Bisbiotin dissolving in water. In aqueous solution (a good solvent), the 
OEG chain likely adapts a helical structure with its –O-C-C-O- backbone folded into a 
trans-gauche-trans conformation141 142 so the Flory radius (Rf)
143 of a OEG chain with 6 
units of ethylene glycol can be estimated as  
                  Rf = N
3/5 (monomer length) = 63/5 x 2.78 = 8.1 Å 
    Thus, the span (~17+8.1Å) between the two biotins in y-Bisbiotin should be wide 
enough for them to simultaneously bind to the streptavidin in aqueous solution without be 
strained. In the present study, we used the stem (Figure 41-D) to immobilize the y-
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Bisbiotin on an SPR chip for studying kinetics of the bivalent interaction and to attach the 
y-Bisbiotin molecule to an atomic force microscopy (AFM) tip for studying the bivalent 
interactions at a single molecule level (vide infra). 
Synthesis. We first synthesized the scaffold, to which two biotin molecules were then 
attached to form the y-Bisbiotin. As shown in Scheme 4.2.1, under the Sonogashira 
cross-coupling conditions,144,145 3,5-diethynylaniline (1)146 reacted with p-iodobenzyloxy-
(OEG)6-NHBoc (2, see its synthesis in experimental section), to produce compound 3 in 
a 75% yield. In the presence of pyridine, the arylamine of compound 3 reacted with α-
OEGylated acetyl chloride S7a and S7b (see experimental section for their synthesis) 
respectively, generating 4a (59%) and 4b (69%), which were subsequently treated with 
trifluoroacetic acid to remove the Boc protecting groups, resulting in the scaffold 
molecules 5a (69%) and 5b (70%). The desired y-Bisbiotin ligands 6a and 6b were 
produced via 5a and 5b reacting with biotin N-hydroxysuccinimide ester in a yield of ~ 
62% and 67%, respectively. The molecules 6a and 6b differ in the length of their stems, 
used to study the bivalent interactions with streptavidin by gel electrophoresis and AFM, 
respectively.  
  
98 
 
Scheme 4.2.1. Synthesis of y-bisbiotin ligands. 
Reagents and conditions: (i) Pd(PPh3)2Cl2, CuI, THF : Et3N = 1:1, rt, 5 h; (ii) S7a or 
S7b, pyridine in dichloromethane, rt, 12 h; (iii) trifluoroacetic acid, rt, 10 min; (iv) biotin 
N-hydroxysuccinimide ester, triethylamine, DMF, rt, 3 h.  
4.2.3. Experimental Section  
General information. All chemicals were purchased as reagent grade and used without 
further purification unless otherwise noted. The Sure/SealTM anhydrous solvents were 
purchased from Sigma-Aldrich. All reactions were performed under an atmosphere of 
argon using the standard Schlenk technique. 1H and 13C NMR spectra were recorded at 
400 MHz (1H) and 100 MHz (13C), respectively. Chemical shifts are given in parts per 
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million (ppm) on the delta scale (δ) and referred either to tetramethylsilane (1H and 13C 
NMR δ = 0 ppm) or the residual solvent peak. High-resolution mass spectra (HRMS) 
were acquired at the Arizona State University CLAS High Resolution Mass Spectrometry 
Facility. MALDI-TOF analysis was performed on Voyager-DE STR instrument at 
Biodesign Institute of Arizona State University. Streptavidin and Dulbecco’s phosphate 
buffered saline solution (PBS, pH 7.4) were purchased form Sigma-Aldrich. 
Special note on nomenclature. To avoid excessive use of a long series of numbers, the 
mathematical shorthand for expressing arithmetic progressions is used to denote the 
positions of oxygen atoms in the elongated PEG chains, as proposed by Hill and co-
workers.73 
Synthesis of 1-(tert-butoxycarbonylamino)-17-p-iodobenzyloxy-3n153-
pentaoxaheptadecane (2). 
 
Scheme 4.2.2. Synthesis of 1-(tert-butoxycarbonylamino)-17-p-iodobenzyloxy-3n15
3-
pentaoxaheptadecane (2). 
1-Azido-17-p-iodobenzyloxy-3n153-pentaoxaheptadecane (S2). Potassium tert-butoxide 
(1.26 g, 11.27 mmol) was added to a solution of 4-iodobenzyl alcohol (2.23 g, 9.5 mmol) 
in anhydrous THF (25 mL) followed by addition of S1 147 (4.0 g, 8.6 mmol) and the 
mixture was stirred at room temperature for 5 h, concentrated by rotary evaporation. The 
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residue was purified by flash chromatography using a gradient of methanol (0-2.5% over 
4 h) in dichloromethane to give S2 as colorless oil (3.17 g, 70%). 1H NMR (400 MHz, 
CDCl3): δ 3.37 (t, 2H, J = 5.2 Hz), 3.58-3.68 (m, 22H), 4.50 (s, 2H ), 7.10 (d, 2H, J = 8 
Hz), 7.66 (d, 2 H, J = 8 Hz). 13C NMR (100 MHz, CDCl3): δ 40.3, 69.5, 70.0, 70.5-70.6, 
72.4, 129.5, 129.8, 137.4, 138.0. HRMS (APCI) (M+H): found m/z 524.1253, calcd for 
C19H30+1IN3O6 524.1254. 
1-Amino-17-p-iodobenzyloxy-3n153-pentaoxaheptadecane (S3). To a solution of S2 
(3 g, 5.7 mmol) in anhydrous THF (20 mL), triphenylphosphine (2.25 g, 8.6 mmol) was 
added and stirred at room temperature for 12 h. Water (1 mL) was added to the mixture, 
which was stirring for another 4 h, concentrated by rotary evaporation. The crude product 
was purified by flash chromatography using a gradient of methanol (0-20% over 4 h) in 
dichloromethane to give S3 as colorless oil (2 g, 70%). 1H NMR (400 MHz, CDCl3): δ 
2.12 (s, 2H), 2.87 (t, 2H, J = 5 Hz), 3.37 (t, 2H, J = 5.2 Hz), 3.58-3.68 (m,  20H), 4.50 (s, 
2H ), 7.10 (d, 2H, J = 8 Hz), 7.66 (d, 2H , J = 8 Hz); 13C NMR (100MHz, CDCl3): δ 40.4, 
69.5, 70.1, 70.5-70.6, 72.4, 129.5, 129.8, 137.4, 138.0. HRMS (APCI) (M+H): found m/z 
498.1334, calcd for C19H32+1INO6 498.1335. 
1-(tert-butoxycarbonylamino)-17-p-iodobenzyloxy-3n153-pentaoxaheptadecane (2). 
To a solution of S3 (2.0 g, 4 mmol) in anhydrous THF (15 mL), di-tert-butyl dicarbonate 
(2.52 mL, 11 mmol) was added followed by addition of diisopropylamine (0.67 mL, 4.8 
mmol). The solution was stirred at room temperature for 15 h, concentrated by rotary 
evaporation. The residue was purified by flash chromatography using a gradient of 
methanol (0-5% over 4 h) in dichloromethane to give 2 as colorless oil (2.1 g, 87%). 1H 
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NMR (400 MHz, CDCl3): δ 1.44 (s, 9H), 3.28-3.32 (m, 2H), 3.48 (t, 2H, J = 5.2 Hz), 
3.49-3.68 (m, 20H), 4.50 (s, 2H ), 5.11 (s, 1H), 7.10 (d, 2H, J = 8 Hz), 7.66 (d, 2 H, J = 8 
Hz); 13C NMR (100 MHz, CDCl3): δ 28.4, 40.3, 68.9, 69.5, 70.1, 70.5-70.6, 72.4, 129.5, 
129.8, 137.4, 138.0, 155.9. HRMS (APCI) (M+H): found m/z 598.1863, calcd for 
C24H40+1INO8 598.1867. 
Synthesis of 20-azido-3n183-hexaoxaicosan-1-oyl chloride (S7a) and 56-azido-3n543-
octadecaoxahexapentacontan-1-oyl chloride (S7b).  
These two compounds were synthesized following a route as described in Scheme S2 and 
Scheme S3. 
 
 
Scheme 4.2.3. Synthesis of S4b. 
53-azido-3n513-heptadecaoxatripentacontan-1-ol (S4b). Compound S4b was 
synthesized following a route described in Scheme 4.2.3. The starting material S3b was 
synthesized following a procedure we previously reported. 147 
To a solution of hexaethylene glycol (6.72 g, 23.8 mmol) in anhydrous THF (40 mL), 
Sodium hydride (0.74g, 30.8 mmol) was added and stirred at 0 °C for 1 h. Compound 
S3b (3.5 g, 7.5 mmol) in anhydrous THF (20 mL) was added to the mixture and allowed 
to warm to room temperature, stirred for another 15 h. Methanol (5 mL) was added 
dropwise to stop the reaction. The mixture was concentrated by rotary evaporation, 
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purified in a silica gel column by flash chromatography using a gradient of methanol (0-
3.5% over 4 h) in dichloromethane. Compound S4b was obtained as a colorless liquid 
(2.9 g, 72%). 1H NMR (400 MHz, CDCl3): δ 2.69 (s, 1 H, broad), 3.36 (t, 2 H, J = 5.2 
Hz), 3.53- 3.68 (m, 70 H). 13C NMR (100 MHz, CDCl3): δ 69.5, 70.1, 70.5-70.6, 72.4. 
HRMS (APCI) (M+H): found m/z 836.5330, calcd for C36H73+1N3O18 836.5332. 
 
 
 
 
 
Scheme 4.2.4. Synthesis of S7a and S7b. 
Tert-butyl 20-azido-3n183-hexaoxaicosan-1-oate (S5a). To a solution of compound 
S4a (2 g, 6.5 mmol) in anhydrous THF (10 mL), potassium tert-butoxide (0.54 g, 7.8 
mmol) was added followed by addition of tert-butyl bromoacetate (0.65 mL, 8.8 mmol). 
The mixture was stirred at room temperature for 5 h, and concentrated by rotary 
evaporation. The residue was purified by flash chromatography using a gradient of 
methanol (0-3.3% over 4 h) in dichloromethane to give S5a as colorless oil (1.2 g, 52%). 
1H NMR (400 MHz, CDCl3): δ 1.43 (m, 9H), 3.36 (t, 2 H, J = 5.2 Hz), 3.53-3.68 (m, 
22H), 3.90 (s, 2H ). 13C NMR (100 MHz, CDCl3): δ 28.03, 50.6, 68.9, 69.5, 70.0, 70.5-
70.6, 72.4, 164.5. HRMS (APCI) (M+H): found m/z 422.3463, calcd for C18H35+1N3O8 
422.3465. 
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Tert-butyl 56-azido-3n543-octadecaoxahexapentacontan-1-oate (S5b). To a solution 
of compound S4b (2 g, 2.3 mmol) in anhydrous THF (10 mL), potassium tert-butoxide 
(0.34 g, 3.1 mmol) was added followed by addition of tert-butyl bromoacetate (0.45 mL, 
3.1 mmol). The mixture was stirred at room temperature for 5 h, and concentrated by 
rotary evaporation. The residue was purified by flash chromatography using a gradient of 
methanol (0-3.3% over 4 h) in dichloromethane to give S5b as colorless oil (1.3 g, 57%). 
1H NMR (400 MHz, CDCl3): δ 1.43 (m, 9H), 3.36 (t, 2 H, J = 5.2 Hz), 3.54-3.68  (m, 
70H), 3.91 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 28.4, 50.6, 69.0, 69.5, 70.0, 70.5-
70.6, 72.4, 164.5. HRMS (APCI) (M+H): found m/z 950.6191, calcd for C42H83+1N3O20 
950.6192. 
20-azido-3n183-hexaoxaicosan-1-oic acid (S6a). Compound S5a (1.0 g, 2.4 mmol) 
was dissolved in 10 mL of trifluoroacetic acid and stirred for 4 h at room temperature, 
and concentrated by rotary evaporation. The residue was purified by flash 
chromatography using a gradient of methanol (0-6% over 3 h) in dichloromethane to give 
S6a as colorless oil (0.62 g, 73%). 1H NMR (400 MHz, CDCl3): δ 3.37 (t, 2 H, J = 5.2 
Hz), 3.53-3.69  (m, 22H), 3.93 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 50.6, 69.1, 69.5, 
70.0, 70.5-70.6, 72.4, 166.8. HRMS (APCI) (M+H): found m/z 366.2754, calcd for 
C14H27+1N3O8 366.2759. 
56-Azido-3n543-octadecaoxahexapentacontan-1-oic acid (S6b). Compound S5b (1.0 
g, 1 mmol) was dissolved in 10 mL of trifluoroacetic acid and stirred for 4 h at room 
temperature, and concentrated by rotary evaporation. The residue was purified by flash 
chromatography using a gradient of methanol (0-6% over 3 h) in dichloromethane to give 
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S6b as colorless oil (0.65 g, 69%). 1H NMR (400 MHz, CDCl3): δ 3.37 (t, 2 H, J = 5.2 
Hz), 3.54-3.69  (m, 70H), 3.92 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 50.6, 68.9, 69.5, 
70.0, 70.5-70.6, 72.4, 166.7. HRMS (APCI) (M+H): found m/z 894.5636, calcd for 
C38H75+1N3O20 894.5637 
Synthesis of 20-azido-3n183-hexaoxaicosan-1-oyl chloride (S7a). Before use, S6a 
(0.5 g, 1.2 mmol) was dissolved in thionyl chloride (2 mL, 2.7 mmol), stirred for 6 h at 
room temperature, and concentrated by rotary evaporation to furnish S7a as yellowish oil. 
56-azido-3n543-octadecaoxahexapentacontan-1-oyl chloride (S7b). Before use, S6b 
(0.5 g, 0.55 mmol) was dissolved in thionyl chloride (2 mL, 2.7 mmol), stirred for 6 h at 
room temperature, concentrated by rotary evaporation to furnish S7b as yellowish oil. 
Synthesis of 6a and 6b. 
3,5-Bis{4-[19-tert-butoxycarbonylamino-(3n183-1) 
hexaoxanonadecyl]phenylethynyl}aniline (3). To a solution of compound 2 (2.6 g, 4.4 
mmol) in THF (20 mL), 3,5-diethynylaniline 1 (0.3 g, 2.1 mmol), 
bis(triphenylphosphine)palladium(II)dichloride (0.074 g, 0.1 mmol) and copper(I) iodide 
(0.040 g, 0.2 mmol) were added. The mixture was stirred at room temperature for 5 h, 
filtered to remove the precipitate, concentrated by rotary evaporation. The residue was 
purified by flash column chromatography on silica gel using a gradient of methanol (0-
2.8% over 4 h) in dichloromethane as an eluent to give 3 as a colorless oil (1.72 g, 75%). 
1H NMR (400 MHz, CDCl3): δ 1.43 (s, 18H), 3.27-3.32 (m, 4H), 3.52 (t, 4H, J = 5.2 Hz), 
3.58-3.69 (m, 44 H), 4.56 (s, 4H), 5.13 (s, 2H), 6.81 (s, 2H), 7.10 (s, 1H), 7.32 (d, 4H, J = 
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8 Hz), 7.47 (d, 4H, J = 8 Hz); 13C NMR (100 MHz, CDCl3): δ 28.3, 40.3, 69.5, 70.1, 
70.3-70.6, 72.7, 88.9, 90.0, 117.7, 122.2, 124.0, 124.9, 127.4, 131.5, 138.6, 146.5, 155.9; 
HRMS (APCI) (M+H): found m/z 1080.6002, calcd for C58H85+1N3O16 1080.6001. 
N-(3,5-Bis{4-[19-tert-butoxycarbonylamino-(3n183-1)-
hexaoxanonadecyl]phenylethynyl}aniline)-20-azido-3n183-icosan-1-amide (4a). 
Compound S7a (see S2 in Supporting Information for its synthesis) dissolved in 
anhydrous dichloromethane (1 mL) was added to a solution of compound 3 (1.4 g, 1.27 
mmol) in anhydrous dichloromethane (10 mL) and pyridine (98 μL, 1.2 mmol). The 
solution was stirred for 12 h at room temperature, concentrated by rotary evaporation. 
The residue was purified by flash column chromatography on silica gel using a gradient 
of methanol (0-4% over 4 h) in dichloromethane as an eluent to give 4a as a colorless oil 
(1.1 g, 59%). 1H NMR (400 MHz, CDCl3): δ 1.43 (s, 18H), 3.21-3.25 (m, 4H), 3.34 (t, 
6H, J = 5.2 Hz), 3.51-3.78 (m, 62 H), 4.13 (s, 2H), 4.56 (s, 4H), 5.13 (s, 2H), 6.81 (s, 
2H), 7.12 (s, 1H), 7.33 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.85 (s, 1H); 13C NMR 
(100 MHz, CDCl3): δ 28.3, 40.3, 50.6, 69.4, 69.7, 69.9, 70.0, 70.4-70.6, 72.7, 88.9, 90.0, 
117.7, 122.3, 124.1, 124.9, 127.4, 131.6, 138.6, 146.5, 155.9, 168.8. MALDI-MS (M+H): 
found m/z 1427.65, calcd for C72H110+1N6O23 1427.67. 
N-(3,5-Bis{4-[19-amino-(3n183-1)-hexaoxanonadecylphenyl]ethynyl}aniline)-20-
Azido-3n183-icosan-1-amide (5a). Compound 4a (0.50 g, 0.35 mmol) was dissolved in a 
solution of TFA (0.3 mL, 3.3 mmol) and anhydrous dichloromethane (0.2 ml). The 
solution was stirred for 10 minutes at room temperature, and concentrated by rotary 
evaporation. The residue was purified by flash column chromatography using a gradient 
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of methanol (0-13% over 4 h) in dichloromethane as an eluent to give 5a as colorless oil 
(0.30 g, 69%). 1H NMR (400 MHz, CDCl3): δ 2.5 (s, 4H), 3.20-3.25 (m, 4H), 3.34 (t, 6H, 
J = 5.2 Hz), 3.50-3.77 (m, 62 H), 4.13 (s, 2H), 4.56 (s, 4H), 6.80 (s, 2H), 7.11 (s, 1H), 
7.32 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.89 (s, 1H); 13C NMR (100 MHz, CDCl3): 
δ 40.3, 50.6, 69.4, 69.7, 69.9, 70.0, 70.4-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 
124.9, 127.4, 131.6, 138.6, 146.5, 168.8; MALDI-MS (M+H): found m/z 1227.40, calcd 
for C62H94+1N6O19 1227.44. 
N-(3,5-Bis{4-[19-biotinylated-amino-(3n183-1)-
hexaoxanonadecyl]phenylethynyl}aniline) )-20-Azido-3n183-icosan-1-amide (6a). A 
solution of 5a (0.20 g, 0.16 mmol), NHS-Biotin (0.116 g, 0.34 mmol), and triethylamine 
(0.047 mL, 0.34 mmol) in anhydrous DMF (2 mL) was stirred at room temperature for 
2.5 h, and concentrated by rotary evaporation. The residue was purified by flash column 
chromatography on silica gel using a gradient of methanol (0-5% over 4 h) in 
dichloromethane as an eluent to give 6a as a colorless oil (0.17 g, 62%). 1H NMR (400 
MHz, CDCl3): δ 1.30-1.80 (m, 12H), 2.21 (t, 4H, J = 7.1 Hz), 2.72 (d, 2H, J = 12.5 Hz), 
2.86 (dd, 2H, J = 4.8 Hz, J = 12.5 Hz), 3.13-3.17 (m, 2H), 3.21-3.26 (m, 4H), 3.33 (t, 6H, 
J = 5.2 Hz), 3.52-3.78 (m, 62 H), 4.13 (s, 2H), 4.31-4.35 (m, 2H), 4.49-4.53 (m, 2H), 4.58 
(s, 4H), 5.75 (s, 2H), 6.45 (s, 2H), 6.50 (s, 2H), 6.81 (s, 2H), 7.10 (s, 1H), 7.32 (d, 4H, J = 
8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.91 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 25.5, 28.0, 
28.1, 35.8, 39.1, 40.3, 50.6, 55.5, 60.1, 61.7, 69.3, 69.7, 69.9, 70.0, 70.4-70.6, 72.7, 88.9, 
90.0, 117.7, 122.3, 124.1, 124.8, 127.4, 131.6, 138.6, 146.5, 163.9, 168.7, 173.5; 
MALDI-MS (M+H): found m/z 1679.76, calcd for C82H122+1N10O23S2 1679.81. 
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N-(3,5-Bis{4-[19-tert-butoxycarbonylamino-(3n183-1)-
hexaoxanonadecyl]phenylethynyl}aniline)-56-azido-3n543-
octadecaoxahexapentacontan-1-amide (4b). Compound S7b (see S2 in Supporting 
Information for its synthesis) dissolved in anhydrous dichloromethane (0.5 mL) was 
added to a solution of compound 3 (0.66 g, 0.6 mmol) in anhydrous dichloromethane (0.5 
mL) and pyridine (98 μL, 1.2 mmol). The solution was stirred for 12 h at room 
temperature, and then concentrated by rotary evaporation. The residue was purified by 
flash column chromatography on silica gel using a gradient of methanol (0-4% over 4 h) 
in dichloromethane as an eluent to give 4b as a colorless oil (0.76 g, 69%). 1H NMR (400 
MHz, CDCl3): δ 1.43 (s, 18H), 3.20-3.25 (m, 4H), 3.34 (t, 6H, J = 5.2 Hz), 3.52-3.78 (m, 
110 H), 4.13 (s, 2H), 4.56 (s, 4H), 5.13 (s, 2H), 6.80 (s, 2H), 7.12 (s, 1H), 7.32 (d, 4H, J = 
8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.85 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 28.3, 40.3, 
50.6, 69.4, 69.7, 69.9, 70.0, 70.3-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.9, 127.4, 
131.6, 138.6, 146.5, 155.9, 168.9. MALDI-MS (M+H): found m/z 1957.36, calcd for 
C96H158+1N6O35 1957.31. 
N-(3,5-Bis{4-[19-amino-(3n183-1)-hexaoxanonadecyl]phenylethynyl}aniline)-56-
Azido-3n543-octadecaoxahexapentacontan-1-amide (5b). Compound 4b (0.7 g, 0.35 
mmol) was dissolved in a solution of TFA (0.3 ml) and anhydrous dichloromethane (0.2 
ml). The solution was stirred for 10 minutes at room temperature, and then concentrated 
by rotary evaporation. The residue was purified by flash column chromatography using a 
gradient of methanol (0-13% over 4 h) in dichloromethane as an eluent to give 5b as 
colorless oil (0.44 g, 70%). 1H NMR (400 MHz, CDCl3): δ 2.5 (s, 4H), 3.20-3.25 (m, 
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4H), 3.34 (t, 6H, J = 5.2 Hz), 3.50-3.77 (m, 110 H), 4.13 (s, 2H), 4.56 (s, 4H), 6.81 (s, 
2H), 7.11 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.89 (s, 1H); 13C NMR 
(100 MHz, CDCl3): δ 40.3, 50.6, 69.4, 69.7, 69.9, 70.0, 70.3-70.6, 72.7, 88.9, 90.0, 117.7, 
122.3, 124.1, 124.9, 127.4, 131.6, 138.6, 146.5, 168.9; MALDI-MS (M+H): found m/z 
1757.16, calcd for C86H142+1N6O31 1757.07. 
N-(3,5-Bis{4-[19-biotinylated-amino-(3n183-1) 
hexaoxanonadecyl]phenylethynyl}aniline)-56-Azido-3n543 
octadecaoxahexapentacontan-1-amide (6b). To a solution of 5b (0.2 g, 0.11 mmol), 
NHS-Biotin (0.116 g, 0.34 mmol), and triethylamine (0.047 mL, 0.34 mmol) in 
anhydrous DMF (2 mL) was stirred at room temperature for 2.5 h, and concentrated by 
rotary evaporation. The residue was purified by flash column chromatography on silica 
gel using a gradient of methanol (0-5% over 4 h) in dichloromethane as an eluent to give 
6b as a colorless oil (0.17 g, 67%). 1H NMR (400 MHz, CDCl3): δ 1.30-1.80 (m, 12H), 
2.21 (t, 4H, J = 7.1 Hz), 2.72 (d, 2H, J = 12.5 Hz), 2.86 (dd, 2H, J = 4.8 Hz, J = 12.5 Hz), 
3.13-3.17 (m, 2H), 3.21-3.26 (m, 4H), 3.33 (t, 6H, J = 5.2 Hz), 3.52-3.78 (m, 110 H), 
4.13 (s, 2H), 4.30-4.35 (m, 2H), 4.49-4.52 (m, 2H), 4.58 (s, 4H), 5.75 (s, 2H), 6.45 (s, 
2H), 6.50 (s, 2H), 6.81 (s, 2H), 7.09 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 
Hz), 8.90 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 25.5, 28.0, 28.1, 35.8, 39.1, 40.3, 50.6, 
55.5, 60.1, 61.7, 69.3, 69.7, 69.9, 70.0, 70.3-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 
124.8, 127.4, 131.6, 138.6, 146.5, 163.9, 168.8, 173.4; MALDI-MS (M+H): found m/z 
2209.52, calcd for C106H170+1N10O35S2 2209.66. 
4.2.4. Conclusions. 
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Departing from a benzene ring which is one of the most commonly used scaffolds to 
construct multivalent molecules,134,148,149 we extended the structure with phenylethynyl 
groups to create a larger rigid structure, on which small sized antibody mimics can be 
constructed. The phenylacetylene chemistry used in this present study can be extended to 
synthesizing even more complicated and larger scaffolds.150 
We have used the bis-biotin structure to study interactions with streptavidin and 
compared dissociation kinetics and stability with a monobiotin linker. It was observed 
that the Y-shaped bisbiotin ligand can: (1) form a 2:1 complex with streptavidin that was 
thermally more stable than the 4:1 complex composed of monobiotin ligand in solution; 
(2) form an intramolecular bivalent complex which is more stable than its intermolecular 
counterpart on the surface; (3) bind to streptavidin cooperatively. SPR study performed 
with the y-bisbiotin indicates that y-Bisbiotin greatly reduced the dissociation rate (koff), 
resulting in a very stable complex with streptavidin. The increase in residence time 
(1/koff) of a ligand interacting with its receptor is of importance in design of drugs. 
Besides binding affinity, the residence time—the period for which a drug remains bound 
to its target151—has been demonstrated for use as a parameter to determine the efficacy of 
a drug.152,153 
4.3. Biochemical Construction of a Tripod Antibody to target Ebola Virus. 
4.3.1 Introduction 
Ebola virus (EBOV) causes severe hemorrhagic fever with up to 90% lethality, but no 
treatments have been approved for human use. Its 2014 outbreak warned us once more to 
develop effective pre- and post-exposure treatments with urgency. Presently, monoclonal 
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antibody (MAb) cocktails are appealing owing to their proven efficacy in nonhuman 
primates. ZMapp, one of the 3-MAb cocktails (containing MAbs c13C6, c2G4 and c4G7 
produced in plants), has become a household name after it was used to treat two 
Americans who were infected while working in Liberia. However, Zmapp is not widely 
available to patients due to (1) one of the three MAbs expressed poorly and (2) an 
extraordinarily high treatment dosage (12 g per patient) is required. These highlight the 
urgency to optimize the MAb cocktails for greater potency, efficacy, and production. For 
therapeutic MAbs, the EBOV glycoprotein (GP) is their target. The GP forms trimeric 
spikes on the virion surface, in which each monomer is a disulfide-bonded complex of a 
receptor binding subunit (GP1) and a fusion subunit (GP2). Structural studies on how 
Zmapp MAbs bind to GP have revealed that the high-dosage requirement of Zmapp may 
be caused by their relative low affinity-binding to GP due to the architecture and 
distribution of spikes.154,155 Other studies have shown that Mab variants that can bind 
bivalently to a single ENV trimeric spike of HIV-1 exhibit >100 fold increase in 
neutralization potencies due to their ability to perform high-avidity intra-spike 
crosslinking.14 These show that multivalent interactions with class-I viral GP (including 
both HIV-1 and EBOV) increase the potency of MAbs and in turn reduce the 
administering dosage. Hence, we are developing an antibody mimic bearing trivalent 
antigen-binding sites, called tripod antibody (TripodAb) (Fig.42), as an 
immunotherapeutic agent against EBOV to enhance potency and producibility. The 
molecule is derived from a scaffold composed of a rigid tetrahedron core flanked with 
multiple hydrophilic chains. In the structure, three single chain variable fragments (scFv) 
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are linked to the scaffold to form a tripod base, which allows them to concomitantly 
interact with a trimeric GP spike that has a “chalice” configuration. Meanwhile, a human 
IgG1 Fc is installed on the top of the tetrahedron, exerting effector functions of a MAb, 
which has been shown to be critical for the potency of Zmapp MAbs. Unlike a natural 
antibody whose bivalent binding to antigens may be restricted due to antigen architecture 
or density, the antibody mimic we designed should allow the molecule to bind a GP spike 
multivalently and more tightly than MAbs in Zmapp, and leave Fc in the favorable 
position to exert effector functions. Strategies of using full MAbs to improve their 
production, binding-affinity and potency against EBOV have suffered from several 
setbacks: (1) optimization of Zmapp full MAb expression has been unsuccessful despite 
major efforts in both mammalian and plant systems; and (2) the architecture of a full IgG 
MAb is not favorable for at least two MAbs in Zmapp to bind GP spike bivalently while 
retaining effector function, leading to low-antigen affinity and potency. We also used 
non-peptide linkers with a precise length to chemically conjugate three scFVs (homo-tri-
ScFvs or hetero-tri-ScFvs from the three Zmapp MAbs) with a human IgG1 Fc to form a 
tripodAb, rationally designed for high-avidity intra-spike multivalent interactions 
independent of spike architecture and distribution. We believe our synthetic antibody 
would be able to achieve a high level production of anti-EBOV MAb derivatives and 
their high-avidity binding to EBOV, enhancing the efficacy and availability of anti-
EBOV immunotherapeutics. In addition to generating urgently needed therapeutic 
reagents for treating EBOV, this study provides a platform for optimizing MAbs efficacy 
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independent of antigen architecture and density, which should be broadly applicable to 
treatment of other viral disease. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Tripod antibody (TripodAb) as an immunotherapeutic agent against EBOV. 
ScFv: single-chain variable fragment, they are optimally spaced to ensure intraspike 
cross-linking. Fc: from the crystallizable fragment of human IgG1 to exert EBOV killing 
through antibody effector functions. 
4.3.2. Results and discussion. 
Four-arm linker. We have synthesized a tetravalent linking molecule (Ar4) with 
Bicyclo[6,1,0]non-4-yn-9-ylmethanol (BCN) at three ends and (E)-Cyclooct-4-enol 
(TCO) at the other end. 
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Figure48. Structure of 4-arm linker (Ar4) 
 
The central part of the 4 arm linker consists of a C4 symmetric tetraamine molecule (3) 
that can be prepared from 1,3,5,7-tetrakis(4-ethynylphenyl)adamantane (1) in two steps 
by copper catalyzed click chemistry with compound 2 followed by hydrazinolysis. 
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Scheme 4.3.1. Synthesis of compound 4 
Following this compound 4 can be sequentially reacted with TCO-NHS and BCN-NHS 
to obtain compound 6. 
 
 
 
Scheme 4.3.2. Synthesis of compound 6. 
2 
3 
6 5 
4 
  1 4 
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We used c6D8, a protein that binds to mucin-like glycoprotein domains of ebola viruses 
as the single chain variable fragment for our synthetic antibody. The c6D8 protein was 
expressed in plants with a LPETGEE sequence at the C-terminus so that it can be reacted 
with a nucleophile by sortase A enzyme mediated ligation. We chose GGGAz (Az = 
Azidoalanine) as the nucleophiles to site-specifically functionalize the c6D8 protein with 
an azide group so that the protein may be attached to Ar4 by uncatalyzed click chemistry 
reaction between BCN and the azide moiety. By monitoring the amount of catalyst used 
for the reaction we observed that 500 ng of sortase A provided the best yield for reaction 
of 20 g of c6D8 protein. The conversion was monitored by performing a ligation 
reaction followed by mixing the reaction mixture with DBCO functionalized Cy5. The 
amount of ligation is monitored by gel electrophoresis followed by fluorescence imaging 
of the gel to measure the intensity of the bands. 
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Figure 49. Fluorescence gel of sortase A mediated ligation of c6D8 protein. 
Monitoring of the reaction at different time intervals for ligation of 20 g of c6D8 protein 
using 500 ng of sortase A indicated the reaction reached completion after 15 h. 
 
Figure 50. Time course for sortase A mediated reaction. 
We are currently working on reaction between the azide functionalized c6D8 with Ar4. 
4.3.3 Experimental section. 
General Information 
All reagents and solvents were purchased from commercial suppliers (Sigma-Aldrich, 
Alfa Aesar, Fluka, TCI America) and used as received unless otherwise noted. Cy5-
DBCO was purchase from Click Chemistry Tools. Staphylococcus aureus sortase A 
pentamutant was purchased from BPS Bioscience. All peptides used in the study were 
custom synthesized from CPC Scientific. Centrifugal filter units were purchased from 
EMD Millipore. All experiments requiring anhydrous conditions were performed in 
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flame-dried glassware under nitrogen atmosphere. Reactions were monitored by thin 
layer chromatography (TLC) using silica gel precoated on glass plates (EMD Millipore). 
1H NMR and 13C NMR spectra were recorded on Varian INOVA 400 (400 MHz) 
spectrometer at 25 °C. Chemical shifts (δ) are given in parts per million (ppm) and 
referenced to the residual solvent peak (CDCl3, δH = 7.26 ppm; CD3OD, δH = 3.31 ppm; 
DMSO-d6, δH = 2.50 ppm). Coupling constants (J) are expressed in hertz (Hz) and the 
values are rounded to the nearest 0.1 Hz. Splitting patterns are reported as follows: br, 
broad; s, singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q, 
quartet and m, multiplet. High-resolution mass spectra (HRMS) were acquired at the 
Arizona State University CLAS High Resolution Mass Spectrometry Facility. MALDI-
MS was performed using a Bruker MALDI-MS instrument at ASU. Flash 
chromatography was performed in an automated flash chromatography system 
(CombiFlash Rf, Teledyne Isco, Inc.) with silica gel columns (60−120 mesh). RP-HPLC 
analysis and separation were performed with a Zorbax 300SB-C18 column (5 µm, 
9.4x250 mm) in an Agilent 1100 HPLC equipped with UV monitor and fraction 
collector. 
Synthesis of compound 1. Compound 1 was synthesized in four steps starting from 1-
bromoadamantane in four synthetic steps following literature protocol.156 
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Synthesis of compound 2. The synthesis of compound 2 starting from O-(2-
Azidoethyl)nonadecaethylene glycol (compound 2a) is shown in scheme 4.3.3 
 
 
Scheme 4.3.3. Synthesis of compound 2. 
Synthesis of compound 2b. Tosyl chloride (156 mg, 0.81 mmol) is added to solution of 
compound 2a (500 mg, 0.54 mmol) and triethylamine (0.5 mL, 3.59 mmol) in anhydrous 
dichloromethane (5 mL) under nitrogen. The reaction mixture was stirred at room 
temperature for 12 h, and then the solvent was removed by rotary evaporation. The 
residue was purified by silica gel column chromatography using a gradient of 4% 
methanol in dichloromethane over 1 h, giving compound 2b as a colorless liquid (537 
mg, 92% yield). 1H NMR (400 MHz, CDCl3): δ 2.34 (s, 3H); 3.27 (t, 2 H, J = 4.8 Hz); 
3.46-3.58 (m, 76 H); 4.04 (t, 2 H, J = 4.8 Hz); 7.23 (d, 2H, J = 8 Hz); 7.67 (d, 2 H, J = 8 
Hz). 13C NMR (100MHz, CDCl3): δ 144.67, 132.94, 129.74, 127.86, 70.72-70.46, 69.93, 
69.18, 68.55, 50.57, 21.54. 
MALDI-MS. m/z : found 1100.79; calcd. for C47H87N3O22SNa 1101.17 
Synthesis of compound 2. Potassium phthalimide (133.4 mg, 0.72 mmol) is added 
to solution of compound 2b (500 mg, 0.46 mmol) in 5 mL anhydrous DMF under 
nitrogen. The reaction mixture is then heated at 110°C for 15 h following which the 
solvent was removed by rotary evaporation. The residue was purified by silica gel 
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column chromatography using a gradient of 4% methanol in dichloromethane over 
1 h, giving compound 2 as a colorless liquid (390 mg, 80% yield). 1H NMR (400 
MHz, CDCl3): δ 3.32 (t, 2 H, J = 4.8 Hz); 3.51-3.69 (m, 76 H); 3.83 (t, 2 H, J = 5.6 Hz); 
7.66 (dd, 2H, J = 5.6, 2.8 Hz); 7.78 (dd, 2 H, J = 5.6, 2.8 Hz). 13C NMR (100MHz, 
CDCl3): δ 168.15, 133.87, 133.08, 123.15, 70.63-70.51, 67.83, 50.61, 37.19. 
MALDI-MS. m/z : found 1075.60; calcd. for C48H84N4O21Na 1076.09. 
Synthesis of compound 3. Compound 1 (34 mg, 0.064 mmol) is added to a solution 
of compound 2 (300 mg, 0.28 mmol) in 2.5 mL tert-butanol and 2.5 mL water under 
nitrogen. This is followed by the addition of Copper sulfate pentahydrate (7.5 mg, 
0.03 mmol) and Sodium Ascorbate (12 mg, 0.06 mmol). The reaction mixture is 
heated at 90°C for 8 h following which the reaction mixture is filtered and the 
solvent is removed by rotary evaporation. The solid residue is redissolved in a 1:1 
mixture of water and acetonitrile following which the compound is purified by 
semiprep RP-HPLC using a 300SB-C18 column. The product was purified using RP 
HPLC with an eluting system composed of (A) 0.1% TFA in DI water and (B) 0.09% 
TFA in 80:20 acetonitrile: water. The retention time of the product in RP HPLC was 27.6 
min with a mobile phase started at 70% eluent A and 30% eluent B, linearly increasing to 
70% B in 30 min. The purified product was concentrated by rotary evaporation to obtain 
a colorless oil (241 mg, 65% yield). 1H NMR (400 MHz, CDCl3): δ 2.21 (s, 12 H); 3.53-
3.91 (m, 312 H); 4.56 (t, 8 H, J = 4.8 Hz); 7.75 (d, 8H, J = 8.4 Hz); 7.68 (dd, 8 H, J = 5.6, 
3.2 Hz); 7.80 (dd, 8H, J = 5.6, 3.2 Hz); 7.81 (d, 8H, J = 8.4 Hz); 7.95 (s, 4H). 13C NMR 
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(100MHz, CDCl3): δ 168.19, 149.09, 147.37, 133.89, 132.11, 128.78, 125.74, 125.49, 
123.19, 120.83, 70.53, 70.05, 69.53, 67.86, 50.33, 47.17, 39.26, 37.21. 
MALDI-MS. m/z : found 4774.4; calcd. for C234H368N16O84Na 4772.36. 
Synthesis of compound 4. Compound 3 (200 mg, .042 mmol) is dissolved in anhydrous 
ethanol (5 mL) followed by the addition of hydrazine hydrate (36 µL, 0.75 mmol). The 
reaction mixture is heated for 2 h at 60°C following which the reaction mixture is 
filtered and the solvent is removed by rotary evaporation. The solid residue is 
redissolved in a 1:1 mixture of water and acetonitrile following which the 
compound is purified by semiprep RP-HPLC using a 300SB-C18 column. The product 
was purified using RP HPLC with an eluting system composed of (A) 0.1% TFA in DI 
water and (B) 0.09% TFA in 80:20 acetonitrile: water. The retention time of the product 
in RP HPLC was 22.5 min with a mobile phase started at 62% eluent A and 38% eluent 
B, linearly increasing to 45% B in 60 min. The purified product was concentrated by 
rotary evaporation to obtain a colorless oil (107 mg, 60% yield). 1H NMR (400 MHz, 
CDCl3): δ 2.22 (s, 12 H); 3.11-3.15 (m, 8 H); 3.57-3.76 (m, 296 H); 3.92 (t, 8H, J= 4.8 
Hz); 4.59 (t, 8 H, J = 4.8 Hz); 7.01 (s, 12 H); 7.57 (d, 8H, J = 8.4 Hz); 7.80 (d, 8H, J = 8.0 
Hz); 8.08 (s, 4H). 13C NMR (100MHz, CDCl3): δ 149.51, 146.86, 127.70, 126.00, 
125.65, 121.59, 70.48-69.22, 66.75, 50.75, 47.08, 39.88, 39.30. 
MALDI-MS. m/z (M+H): found 4230.67; calcd. for C202H360+1N16O76 4229.06. 
Synthesis of compound 5. Compound 4 (40 mg, 0.009 mmol) is dissolved in anhydrous 
DCM under Nitrogen followed by the addition Triethylamine (0.1 mL, 0.7 mmol) and 
(E)-Cyclooct-4-enyl 2,5-dioxo-1-pyrrolidinyl carbonate (TCO-NHS) (3.6 mg, 0.014 
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mmol) following which the reaction is stirred and room temperature for 12 h. The solvent 
is then removed by rotary evaporation. The solid residue is redissolved in a 1:1 mixture 
of TEAA (0.1 M) and acetonitrile following which the compound is purified by semiprep 
RP-HPLC using a 300SB-C18 column. The product was purified using RP HPLC with an 
eluting system composed of (A) TEAA buffer (0.1 M) and (B) Acetonitrile. The retention 
time of the product in RP HPLC was 17.6 min with a mobile phase started at 70% eluent 
A and 30% eluent B, linearly increasing to 80% B in 60 min. The purified product was 
concentrated by rotary evaporation to obtain a colorless oil. (8 mg, 20% yield). 1H NMR 
(400 MHz, CDCl3): δ 1.47-1.58 (m, 2H); 1.71-1.78 (m, 2H); 1.89-2.05 (m, 4H); 2.23 (s, 
12H); 2.29-2.36 (m, 2H); 2.85-2.90 (m, 2H); 3.32-3.79 (m, 302H); 3.91 (t, 8H, J = 4.8 
Hz); 4.30-4.32 (m, 1H); 4.58 (t, 8H, J = 4.8 Hz); 5.10-5.18 (m, 1H); 5.42-5.76 (m,  H); 
7.56 (d, 8H, J = 8.4 Hz); 7.83 (d, 8H, J =  8.4 Hz), 7.96 (s, 4H) 
MALDI-MS. m/z (M+H): found 4284.7; calcd. for C211H372+1N16O78 4382.25. 
Synthesis of compound 6. Compound 5 (8 mg, 0.0018 mmol) is dissolved in anhydrous 
DCM under Nitrogen followed by the addition Triethylamine (0.1 mL, 0.7 mmol) and 
(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl carbonate 
 (BCN-NHS) (3.6 mg, 0.014 mmol) following which the reaction is stirred and room 
temperature for 12 h. The solvent is then removed by rotary evaporation. The solid 
residue is redissolved in a 1:1 mixture of TEAA (0.01 M) and acetonitrile following 
which the compound is purified by semiprep RP-HPLC using a 300SB-C18 column. The 
product was purified using RP HPLC with an eluting system composed of (A) TEAA 
buffer (0.01 M) and (B) Acetonitrile. The retention time of the product in RP HPLC was 
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33.2 min with a mobile phase started at 65% eluent A and 35% eluent B, linearly 
increasing to 80% B in 60 min. The purified product was concentrated by rotary 
evaporation to obtain a colorless oil. (3.5 mg, 40% yield). 1H NMR (400 MHz, CDCl3): δ 
0.82-0.98 (m, 9H); 1.28-1.42 (m, 6H); 1.47-1.58 (m, 2H); 1.68-1.78 (m,2 H); 1.89-2.05 
(m, 4H); 2.23 (s, 12H); 2.17-2.67 (m, 12H); 2.27-2.38 (m, 8H); 2.83-2.90 (m, 8H); 3.33-
3.82 (m, 296 H); 3.91 (t, 8H, J = 4.8 Hz); 4.13 (d, 6H, J= 8.4 Hz); 4.30-4.32 (m, 1H); 
4.58 (t, 8H, J = 4.8 Hz); 5.10-5.18 (m, 1H); 5.20-5.32 (m, 3H) 5.42-5.76 (m, 2 H); 7.56 
(d, 8H, J = 8.4 Hz); 7.83 (d, 8H, J =  8.4 Hz), 7.97 (s, 4H). 
MALDI-MS. m/z: found 4949.10; calcd. for C244H408N16O84 4949.01. 
Procedure for sortase mediated ligation. Sortase reaction was performed in 50 μL 
buffer solution containing 50 mM HEPES (pH=7.4), 150 mM NaCl, 5 mM CaCl2, 0.5 
mM GGGAz, 24 µM c6D8 protein, and 500 ng Sortase A pentamutant for 15 h at 30°C. 
Following this 5 μL of the reaction mixture is aliquoted with 5 μL of Cy5-DBCO (2 mM) 
for 2 h at room temperature following which the samples is loaded on a SDS-PAGE gel. 
Fluorescence image of the SDS-PAGE gel is obtained. The modified c6D8 protein is 
purified and buffer exchanged to PBS pH 7.4 using 10 kD Amicon ultracentrifugal filters. 
4.3.4. Summary. We have synthesized a 4-arm scaffold in our quest to design a 
chemically synthesized antibody to target Ebola glycoproteins. We are have devised a 
sortase A mediated ligation chemistry to functionalize the protein site-selectively. We are 
currently working on attachment of the proteins to the four arm linker. 
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